

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 April 2002 (11.04.2002)

PCT

(10) International Publication Number
WO 02/29025 A2

(51) International Patent Classification⁷: **C12N 9/64,**
A61K 38/36, C12P 21/02, G01N 33/86

(21) International Application Number: **PCT/DK01/00633**

(22) International Filing Date: 2 October 2001 (02.10.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

PA 2000 01456	2 October 2000 (02.10.2000)	DK
60/238,944	10 October 2000 (10.10.2000)	US
PA 2001 00262	16 February 2001 (16.02.2001)	DK
60/271,581	26 February 2001 (26.02.2001)	US
PA 2001 00430	14 March 2001 (14.03.2001)	DK
60/276,322	16 March 2001 (16.03.2001)	US
PA 2001 00751	14 May 2001 (14.05.2001)	DK

(71) Applicant: NOVO NORDISK A/S [DK/DK]; Novo Allé,
DK-2880 Bagsvaerd (DK).

(72) Inventors: PINGEL, Hans, Kurt; Munkehøjvænge 35,
DK-3520 Farum (DK). KLAUSEN, Niels, Kristian;
Sassvej 14, DK-2820 Gentofte (DK).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA,
ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



A2
WO 02/29025

(54) Title: FACTOR VII GLYCOFORMS

(57) Abstract: The present invention relates to compositions comprising Factor VII and other blood clotting factors having altered patterns of asparagine-linked glycosylation.

FACTOR VII GLYCOFORMS

Field of the Invention

5 The present invention relates to compositions comprising Factor VII and other blood clotting factors having altered patterns of asparagine-linked glycosylation.

Background of the Invention

10 The proteins involved in the clotting cascade, including, e.g., Factor VII, Factor VIII, Factor IX, Factor X, and Protein C, are proving to be useful therapeutic agents to treat a variety of pathological conditions. Accordingly, there is an increasing need for formulations comprising these proteins that are pharmaceutically acceptable and exhibit a uniform and predetermined clinical efficacy.

15 Because of the many disadvantages of using human plasma as a source of pharmaceutical products, it is preferred to produce these proteins in recombinant systems. The clotting proteins, however, are subject to a variety of co- and post-translational modifications, including, e.g., asparagine-linked (N-linked) glycosylation; O-linked glycosylation; and γ -carboxylation of glu residues. These modifications may be qualitatively or quantitatively different when heterologous cells are used as hosts for 20 large-scale production of the proteins. In particular, production in heterologous cells often results in a different array of glycoforms, which are identical polypeptides having different covalently linked oligosaccharide structures.

25 In different systems, variations in the oligosaccharide structure of therapeutic proteins have been linked to, *inter alia*, changes in immunogenicity and *in vivo* clearance. Thus, there is a need in the art for compositions and methods that provide clotting protein preparations, particularly preparations comprising recombinant human Factor VII, modified Factor VII, or Factor VII-related polypeptides, that contain predetermined glycoform patterns.

Summary of the Invention

30 The present invention relates to preparations comprising Factor VII polypeptides or Factor VII-related polypeptides that exhibit predetermined glycoform patterns. As used herein, a Factor VII or Factor VII-related preparation refers to a plurality of Factor VII or Factor VII-related polypeptides, including variants and chemically modified forms, as well as forms that have been proteolytically activated (e.g., Factor VIIa), that have 35 been separated from the cell in which they were synthesized. A glycoform pattern refers to the distribution within the preparation of oligosaccharide chains having varying

structures that are covalently linked to Factor VII polypeptides or Factor VII-related polypeptides.

In one aspect, the invention provides a preparation comprising a plurality of Factor VII polypeptides or Factor VII-related polypeptides, wherein the polypeptides comprise asparagine-linked oligosaccharide chains and wherein one or more of the following applies: (i) between about 94-100% of the oligosaccharide chains comprise at least one sialic acid moiety; (ii) between about 0-7% of the oligosaccharide chains have a neutral charge; (iii) less than about 16%, such as, e.g., between about 6-16% of the oligosaccharide chains comprise at least one terminal galactose residue; (iv) less than about 25%, such as, e.g., between about 6-9% of the oligosaccharide chains comprise at least one terminal N-acetylgalactosamine residue; or (v) less than about 30%, such as, e.g., between about 11-23% of the oligosaccharide chains comprise at least one terminal galactose or N-acetylgalactosamine residue. In some embodiments, in addition to one or more of (i)-(v): all of the sialic acid residues in the oligosaccharide chains are linked to galactose via an α 2->3 linkage; at least some of the sialic acid residues comprise N-glycolylneuraminic acid (Neu5Gc) in addition to N-acetylneuraminic acid (Neu5Ac); and/or the oligosaccharide chains comprise fucose residues linked α 1->6 to a core N-acetylglucosamine. In one embodiment, the invention encompasses a preparation comprising wild-type Factor VIIa in which between about 94-100% of the oligosaccharide chains have at least one sialic acid residue and all of the sialic acid residues are linked to galactose via an α 2->3 linkage. In another embodiment, the invention encompasses a preparation comprising wild-type Factor VIIa in which between about 94-100% of the oligosaccharide chains have at least one sialic acid residue and at least some of the sialic acid residues are N-glycolylneuraminic acid. In yet another embodiment, the invention encompasses a preparation comprising wild-type Factor VIIa in which between about 94-100% of the oligosaccharide chains have at least one sialic acid residue and at least some of the chains contain N-acetylgalactosamine. The preparations of the present invention thus do not encompass wild-type Factor VII or Factor VIIa that has been isolated from human plasma and has not been modified *ex vivo* by glycosidase treatment.

In another aspect, the invention provides a preparation comprising a plurality of Factor VII polypeptides or Factor VII-related polypeptides, wherein the polypeptides comprise asparagines-linked oligosaccharide chains and wherein at least about 2% of the oligosaccharide chains contain at least one fucose linked α 1->3 to an antennary N-acetylglucosamine residue (i.e., an N-acetylglucosamine residue that is linked β 1->2,4,

or 6 to a Man residue). Preferably, at least about 5% of the oligosaccharide chains contain at least one such antennary fucose residue; more preferably, at least about 10% or 20%; and most preferably, at least about 40%.

The preparations according to invention may comprise one or more of unmodified wild-type Factor VII; wild-type Factor VII that has been subjected to chemical and/or enzymatic modification; and Factor VII variants having one or more alterations in amino acid sequence relative to wild-type Factor VII. The preparations of the invention may be derived from human cells expressing Factor VII from an endogenous Factor VII gene or from cells programmed to express Factor VII or a Factor VII-related polypeptide 10 from a recombinant gene.

In another aspect, the invention provides preparations comprising Factor VII or Factor VII-related polypeptides that exhibit one or more improved functional properties, including, without limitation, increased storage stability, bioavailability, and/or half-life.

In another aspect, the invention encompasses methods for determining and/or 15 optimizing the glycoform pattern of Factor VII and Factor VII-related polypeptides, which are carried out by the steps of:

- (a) culturing a cell expressing Factor VII or Factor VII-related polypeptides under a first set of predetermined culture conditions;
- (b) recovering Factor VII or Factor VII-related polypeptides from the culture to obtain 20 a preparation comprising the polypeptides; and
- (c) analyzing the structure of the oligosaccharides linked to the polypeptides to determine the glycoform pattern of the preparation.

The methods may further comprise altering the culture conditions of step (a) to achieve a second set of predetermined culture conditions; and repeating the steps until a desired glycoform pattern is achieved. Alternatively, the methods may further comprise treating the preparation chemically or enzymatically to alter the oligosaccharide structure; and repeating the steps until a desired glycoform pattern is achieved. Furthermore, the methods may comprise the additional steps of subjecting preparations having predetermined glycoform patterns to at least one test of bioactivity or other functionality (such as, e.g., pharmacokinetic profile or stability), and correlating particular glycoform patterns with particular bioactivity or functionality profiles.

In another aspect, the invention provides methods for producing a preparation comprising Factor VII polypeptides or Factor VII-related polypeptides having a predetermined pattern of N-linked glycosylation. In some embodiments, the methods are carried out by culturing a cell expressing the polypeptides under conditions in which at least about 94% of the 35

asparagine-linked oligosaccharides linked to the Factor VII polypeptides or Factor VII-related polypeptides comprise at least one sialic acid residue, e.g., one, two, three, or four sialic acid residues. In some embodiments, the methods are carried out by culturing a cell expressing the polypeptides under conditions in which at least about 5% of the oligosaccharide chains 5 contain at least one fucose linked α 1->3 to an antennary N-acetylglucosamine residue. In some embodiments, Factor VII polypeptides or Factor VII-related polypeptides, irrespective of their source, are subjected to enzymatic treatments to achieve the desired glycoform patterns.

In another aspect, the invention provides pharmaceutical formulations comprising 10 the preparations of the invention and methods of preventing and/or treating syndromes that are responsive to Factor VII polypeptides or Factor VII-related polypeptides. The methods comprise administering the pharmaceutical formulations to a patient in need of treatment, under conditions that result in either an enhancement or inhibition in blood clotting. In one series of embodiments, Factor VII preparations are administered when it is desired to enhance blood clotting, such as, e.g., in haemophilia A, haemophilia B, Factor XI deficiency, 15 Factor VII deficiency, thrombocytopenia, or von Willebrand's disease; in syndromes accompanied by the presence of a clotting factor inhibitor; before, during, or after surgery or anticoagulant therapy; or after trauma. In another series of embodiments, preparations of Factor VII-related polypeptides (i.e., preparations having reduced or modified bioactivity relative to 20 wild-type Factor VII) are administered to reduce blood clotting, such as, e.g., in patients undergoing angioplasty or those suffering from deep vein thrombosis, pulmonary embolism, stroke, disseminated intravascular coagulation (DIC), fibrin deposition in lungs and kidneys associated with gram-negative endotoxemia, or myocardial infarction. According to the invention, preparations of Factor VII-related polypeptides may also be administered when it is 25 desired to modify, such as, e.g., reduce, intracellular signalling via a tissue factor (TF)-mediated pathway, to treat conditions such as, e.g., Acute Respiratory Distress Syndrome (ARDS), Systemic Inflammatory Response Syndrome (SIRS), Hemolytic Uremic Syndrome (HUS), Multiple Organ Failure (MOF), and thrombocytopenia purpura (TTP).

30 **Detailed Description of the Invention**

The present inventors have discovered that preparations of coagulation proteins having predetermined glycoform patterns exhibit improved functional properties. Accordingly, the present invention relates to methods and compositions that provide these protein preparations. In particular, the invention relates to preparations comprising Factor VII polypeptides and Factor VII-related polypeptides having specific predetermined patterns of as- 35

paragine-linked (N-linked) oligosaccharides. The preparations of the invention exhibit altered properties, including, without limitation, improved pharmacokinetic properties and improved clinical efficacy. The invention also encompasses pharmaceutical formulations that comprise these preparations, as well as therapeutic methods that utilize the formulations.

5

Factor VII Polypeptides and Factor VII-Related Polypeptides

The present invention encompasses human Factor VII polypeptides, such as, e.g., those having the amino acid sequence disclosed in U.S. Patent No. 4,784,950 (wild-type Factor VII). As used herein, "Factor VII" or "Factor VII polypeptide" encompasses wild-type Factor VII, as well as variants of Factor VII exhibiting substantially the same or improved biological activity relative to wild-type Factor VII. The term "Factor VII" is intended to encompass Factor VII polypeptides in their uncleaved (zymogen) form, as well as those that have been proteolytically processed to yield their respective bioactive forms, which may be designated Factor VIIa. Typically, Factor VII is cleaved between residues 152 and 153 to yield Factor VIIa.

As used herein, "Factor VII-related polypeptides" encompasses polypeptides, including variants, in which the Factor VIIa biological activity has been substantially modified or reduced relative to the activity of wild-type Factor VIIa. These polypeptides include, without limitation, Factor VII or Factor VIIa that has been chemically modified and Factor VII variants into which specific amino acid sequence alterations have been introduced that modify or disrupt the bioactivity of the polypeptide.

The biological activity of Factor VIIa in blood clotting derives from its ability to (i) bind to tissue factor (TF) and (ii) catalyze the proteolytic cleavage of Factor IX or Factor X to produce activated Factor IX or X (Factor IXa or Xa, respectively). For purposes of the invention, Factor VIIa biological activity may be quantified by measuring the ability of a preparation to promote blood clotting using Factor VII-deficient plasma and thromboplastin, as described, e.g., in U.S. Patent No. 5,997,864. In this assay, biological activity is expressed as the reduction in clotting time relative to a control sample and is converted to "Factor VII units" by comparison with a pooled human serum standard containing 1 unit/ml Factor VII activity. Alternatively, Factor VIIa biological activity may be quantified by (i) measuring the ability of Factor VIIa to produce of Factor Xa in a system comprising TF embedded in a lipid membrane and Factor X. (Persson et al., *J. Biol. Chem.* 272:19919-19924, 1997); (ii) measuring Factor X hydrolysis in an aqueous system (see, Example 5 below); (iii) measuring its physical binding to TF using an instrument based on surface plasmon resonance (Persson, *FEBS Letts.* 413:359-363, 1997) (iv)

measuring hydrolysis of a synthetic substrate (see, Example 4 below); and (v) measuring generation of thrombin in a TF-independent in vitro system.

Factor VII variants having substantially the same or improved biological activity relative to wild-type Factor VIIa encompass those that exhibit at least about 25%, preferably at least about 50%, more preferably at least about 75% and most preferably at least about 90% of the specific activity of wild-type Factor VIIa that has been produced in the same cell type, when tested in one or more of a clotting assay, proteolysis assay, or TF binding assay as described above. Factor VII variants having substantially reduced biological activity relative to wild-type Factor VIIa are those that exhibit less than about 25%, preferably less than about 10%, more preferably less than about 5% and most preferably less than about 1% of the specific activity of wild-type Factor VIIa that has been produced in the same cell type when tested in one or more of a clotting assay, proteolysis assay, or TF binding assay as described above. Factor VII variants having a substantially modified biological activity relative to wild-type Factor VII include, without limitation, Factor VII variants that exhibit TF-independent Factor X proteolytic activity and those that bind TF but do not cleave Factor X.

Variants of Factor VII, whether exhibiting substantially the same or better bioactivity than wild-type Factor VII, or, alternatively, exhibiting substantially modified or reduced bioactivity relative to wild-type Factor VII, include, without limitation, polypeptides having an amino acid sequence that differs from the sequence of wild-type Factor VII by insertion, deletion, or substitution of one or more amino acids. Non-limiting examples of Factor VII variants having substantially the same biological activity as wild-type Factor VII include S52A-FVIIa, S60A-FVIIa (Iino et al., *Arch. Biochem. Biophys.* 352: 182-192, 1998); FVIIa variants exhibiting increased proteolytic stability as disclosed in U.S. Patent No. 5,580,560; Factor VIIa that has been proteolytically cleaved between residues 290 and 291 or between residues 315 and

Asparagine-Linked Glycosylation

The present invention provides preparations of Factor VII polypeptides or Factor VII-related polypeptides that comprise a particular spectrum of Factor VII glycoforms, i.e., Factor VII polypeptides or Factor VII-related polypeptides having predetermined patterns of asparagine-linked (N-linked) oligosaccharide chains.

As used herein, a "pattern" of N-linked glycosylation or a glycoform "pattern", "distribution", or "spectrum" refers to the representation of particular oligosaccharide structures within a given population of Factor VII polypeptides or Factor VII-related polypeptides. Non-limiting examples of such patterns include the relative proportion of oligosaccharide chains that (i) have at least one sialic acid residue; (ii) lack any sialic acid residues (i.e., are neutral in charge); (iii) have at least one terminal galactose residue; (iv) have at least one terminal N-acetylgalactosamine residue; (v) have at least one "uncapped" antenna, i.e., have at least one terminal galactose or N-acetylgalactosamine residue; or (vi) have at least one fucose linked α 1->3 to an antennary N-acetylgalucosamine residue.

As used herein, an oligosaccharide chain refers to the entire oligosaccharide structure that is covalently linked to a single asparagine residue. Factor VII is normally glycosylated at Asn 145 and Asn 322. An N-linked oligosaccharide chain present on Factor VII produced in a human *in situ* may be bi-, tri, or tetraantennary, with each antenna having the structure Neu5Ac(α 2->3 or α 2->6)Gal(β 1->4) GlcNAc linked (β 1->2,4, or 6) to a Man residue which is linked (α 1->3 or 6) to Man(β 1->4)GlcNAc(β 1->4)GlcNAc-Asn. (Neu5Ac signifies N-acetylneuraminic acid (sialic acid), Gal signifies galactose, GlcNAc signifies N-acetylgalucosamine, and Man signifies mannose). The oligosaccharide chains may also comprise fucose residues, which may be linked α 1->6 to GlcNAc. When Factor VII is produced in a human *in situ*, some of the oligosaccharide chains lack core fucose residues; all of the chains lack antennary fucose residues; and all of the chains are almost completely sialylated, i.e., the terminal sugar of each antenna is N-acetylneuraminic acid linked to galactose via an α 2->3 or α 2->6 linkage.

When produced in other circumstances, however, Factor VII may contain oligosaccharide chains having different terminal structures on one or more of their antennae, such as, e.g., lacking sialic acid residues; containing N-glycolylneuraminic acid (Neu5Gc) residues; containing a terminal N-acetylgalactosamine (GalNAc) residue in place of galactose; and the like. When produced in, e.g., BHK cells cultured in the presence of calf serum, Factor VII preparations exhibit the following oligosaccharide patterns:

- 87-93% of the oligosaccharide chains contain at least a single sialic acid residue;
- 35 --7-13% are neutral (lack any sialic acid);

--9-16% contain at least one terminal galactose residue;
--19-29% contain at least one terminal N-acetylgalactosamine residue; and
--30-39% contain at least one uncapped antenna, i.e., contain at least one terminal galactose or N-acetylgalactosamine residue.

5 The present inventors have produced Factor VII preparations containing specific predetermined oligosaccharide patterns that differ from those previously described. The present invention encompasses preparations comprising Factor VII polypeptides or Factor VII-related polypeptides exhibiting one or more of the following glycoform patterns:

10 (i) Between about 94-100% of the oligosaccharide chains contain at least one sialic acid residue, such as, e.g., between about 94-99%, between about 95-98%, or between about 96-97%. In different embodiments, at least about 94%, 95%, 96%, or 97% of the oligosaccharide chains contain at least one sialic acid residue.

15 (ii) 6% or less of the oligosaccharide chains are neutral, such as, e.g., between about 1.5-6% or between about 2-4%.

19 (iii) Less than about 16%, preferably, less than about 10% of the oligosaccharide chains contain at least one terminal galactose, such as, e.g., between about 6-10% or between about 8-9%;

20 (iv) Less than about 25%, preferably, less than about 10% of the oligosaccharide chains contain at least one terminal GalNAc residue, such as, e.g., between about 6-9% or between about 7-8%;

(v) Less than about 30, preferably, less than about 25% of the oligosaccharide chains contain at least one uncapped antenna, such as, e.g., between about 11-23% or between about 12-18%; and

25 (vi) At least about 2%, preferably, at least about 5%, more preferably, at least about 10% or 20%; and most preferably, at least about 40%, of the oligosaccharide chains contain at least one fucose linked α 1->3 to an antennary N-acetylglucosamine residue (i.e., an N-acetylglucosamine residue that is linked β 1->2,4, or 6 to a Man residue).

It will be understood that each of (i)-(vi) may represent a distinct glycoform pattern that is encompassed by the present invention, i.e., a preparation according to the invention may be described by only one of (i)-(vi). Alternatively, depending on the particular glycoform pattern, a preparation encompassed by the invention may be described by more than one of (i)-(vi).

Furthermore, a preparation encompassed by the invention may be described by one or more of (i)-(vi) in combination with one or more other structural features. For example, the

invention encompasses preparations comprising Factor VII polypeptides or Factor VII-related polypeptides in which the sialic acid residues (Neu5Ac or Neu5Gc) are linked to galactose exclusively in an α 2->3 configuration. The invention also encompasses preparations comprising Factor VII polypeptides or Factor VII-related polypeptides that contain fucose linked α 5 1->6 to a core N-acetylglucosamine and/or fucose linked α 1->3 to an antennary N-acetylglucosamine. In one series of embodiments, the preparations of the invention encompass Factor VII or Factor VII-related polypeptides in which more than 99% of the oligosaccharide chains contain at least one sialic acid residue *and* (a) the sialic acid residues are linked exclusively in an α 2->3 configuration and/or (b) there are fucose residues linked to 10 core N-acetylglucosamines and/or (c) a detectable number of antenna terminate in N-acetylgalactosamine. In one embodiment, the invention encompasses preparations comprising wild-type Factor VIIa in which more than 99% of the oligosaccharide chains contain at least one sialic acid residue and the sialic acid residues are linked to galactose exclusively in an α 2->3 configuration. In another embodiment, the invention encompasses preparations 15 comprising wild-type Factor VIIa in which more than 99% of the oligosaccharide chains contain at least one sialic acid residue and at least some of the oligosaccharide chains comprise N-acetylgalactosamine. The present invention does not encompass wild-type Factor VII or wild-type Factor VIIa that is isolated from human plasma and is not modified *ex vivo* by treatment with glycosidases.

20 In one embodiment, the Factor VIIa preparation comprises oligosaccharide chains having a single fucose linked α 1->3 to one antennary N-acetylglucosamine. In another embodiment, the Factor VIIa preparation comprises oligosaccharide chains having fucose residues linked α 1->3 to each antennary N-acetylglucosamine of a biantennary oligosaccharide (Sialyl Lewis X structure). In another embodiment, the Factor VIIa preparation comprises 25 oligosaccharide chains having (i) a fucose linked to a core N-acetylglucosamine and (ii) a single fucose linked α 1->3 to one antennary N-acetylglucosamine. In another embodiment, the Factor VIIa preparation comprises oligosaccharide chains having (i) a fucose linked to a core N-acetylglucosamine and (ii) fucose residues linked α 1->3 to each antennary N-acetylglucosamine of a biantennary oligosaccharide.

30 In practicing the present invention, the pattern of N-linked oligosaccharides may be determined using any method known in the art, including, without limitation: high-performance liquid chromatography (HPLC); capillary electrophoresis (CE); nuclear magnetic resonance (NMR); mass spectrometry (MS) using ionization techniques such as fast-atom bombardment, electrospray, or matrix-assisted laser desorption (MALDI); gas chromatogra-

phy (GC); and treatment with exoglycosidases in conjunction with anion-exchange (AIE)-HPLC, size-exclusion chromatography (SEC), or MS. See, e.g., Weber et al., *Anal. Biochem.* 225:135 (1995); Klausen et al., *J. Chromatog.* 718:195 (1995); Morris et al., in *Mass Spectrometry of Biological Materials*, McEwen et al., eds., Marcel Dekker, (1990), pp 137-5 167; Conboy et al., *Biol. Mass Spectrom.* 21:397, 1992; Hellerqvist, *Meth. Enzymol.* 193:554 (1990); Sutton et al., *Anal. Biochem.* 318:34 (1994); Harvey et al., *Organic Mass Spectrometry* 29:752 (1994).

Following resolution of Factor VII-derived oligosaccharide chains using any of the above methods (or any other method that resolves oligosaccharide chains having 10 different structures), the resolved species are assigned, e.g., to one of groups (i)-(v). The relative content of each of (i)-(v) is calculated as the sum of the oligosaccharides assigned to that group relative to the total content of oligosaccharide chains in the sample.

For example, using AIE-HPLC, 13 or more N-linked oligosaccharide peaks can be 15 resolved from a recombinant Factor VII preparation produced in BHK cells. See, e.g., Klausen et al., *Mol. Biotechnol.* 9:195, 1998. Five of the peaks (designated 1-5 in Klausen et al.) do not contain sialic acid, while eight of the peaks (designated 6, 7, and 10-15) do contain sialic acid.

It will be understood that, in a given analysis, the number and distribution of sialic 20 acid-containing and sialic acid-lacking chains may depend upon (a) the polypeptide being expressed; (b) the cell type and culture conditions; and (c) the method of analysis that is employed, and that the resulting patterns may vary accordingly.

In any case, once the sialic acid-containing oligosaccharides have been resolved 25 from the non-sialic acid-containing oligosaccharides, conventional data analysis programs are used to calculate the area under each peak; the total peak area; and the percentage of the total peak area represented by a particular peak. In this manner, for a given preparation, the sum of the areas of sialic acid-containing peaks/total peak area X 100 yields the % sialylation value for the preparation according to the present invention (i.e., the proportion of oligosaccharide chains having at least one sialic acid residue). 30 In a similar manner, the % of chains having no sialic acid or at least one galactose or N-acetylglucosamine can be calculated.

Methods for Producing Factor VII Preparations Having a Predetermined Pattern of N-linked Oligosaccharides

Preparations of Factor VII, Factor VII variants, or Factor VII-related polypeptides, each having a predetermined pattern of N-linked oligosaccharides, may be produced using any appropriate host cell that expresses Factor VII or Factor VII-related polypeptides.

Host cells: In some embodiments, the host cells are human cells expressing an endogenous Factor VII gene. In these cells, the endogenous gene may be intact or 10 may have been modified *in situ*, or a sequence outside the Factor VII gene may have been modified *in situ* to alter the expression of the endogenous Factor VII gene. Any human cell capable of expressing an endogenous Factor VII gene may be used.

In other embodiments, heterologous host cells are programmed to express human Factor VII from a recombinant gene. The host cells may be vertebrate, insect, or fungal 15 cells. Preferably, the cells are mammalian cells capable of the entire spectrum of mammalian N-linked glycosylation; O-linked glycosylation; and γ -carboxylation. See, e.g., U.S. Patent Nos. 4,784,950. Preferred mammalian cell lines include the CHO (ATCC CCL 61), COS-1 (ATCC CRL 1650), baby hamster kidney (BHK) and HEK293 (ATCC CRL 1573; Graham et al., *J. Gen. Virol.* 36:59-72, 1977) cell lines. A preferred BHK cell line is the tk⁻ ts13 BHK cell 20 line (Waechter and Baserga, *Proc. Natl. Acad. Sci. USA* 79:1106-1110, 1982), hereinafter referred to as BHK 570 cells. The BHK 570 cell line is available from the American Type Culture Collection, 12301 Parklawn Dr., Rockville, MD 20852, under ATCC accession number CRL 10314. A tk⁻ ts13 BHK cell line is also available from the ATCC under accession number CRL 1632. In addition, a number of other cell lines may be used, including Rat Hep I 25 (Rat hepatoma; ATCC CRL 1600), Rat Hep II (Rat hepatoma; ATCC CRL 1548), TCMK (ATCC CCL 139), Human lung (ATCC HB 8065), NCTC 1469 (ATCC CCL 9.1) and DUKX cells (CHO cell line) (Urlaub and Chasin, *Proc. Natl. Acad. Sci. USA* 77:4216-4220, 1980). (DUKX cells also referred to as CXB11 cells), and DG44 (CHO cell line) (*Cell*, 33:405, 1983, and *Somatic Cell and Molecular Genetics* 12:555, 1986). Also useful are 3T3 cells, 30 Namalwa cells, myelomas and fusions of myelomas with other cells. In a particularly preferred embodiment, the host cells are BHK 21 cells that have been adapted to grow in the absence of serum and have been programmed to express Factor VII. In some embodiments, the cells may be mutant or recombinant cells that express a qualitatively or quantitatively different spectrum of glycosylation enzymes (such as, e.g., glycosyl transferases and/or glycosidases) 35 than the cell type from which they were derived. The cells may also be programmed to express other heterologous peptides or proteins, including, e.g., truncated forms of Factor VII.

In one embodiment, the host cells are CHO cells that have been programmed to co-express both the Factor VII polypeptide of interest (i.e., Factor VII or a Factor-VII-related polypeptide) and another heterologous peptide or polypeptide such as, e.g., a modifying enzyme or a Factor VII fragment.

5 Methods: The present invention encompasses methods for producing a preparation comprising any of the glycoform patterns described above as (i)-(vi) and, in further embodiments, methods for optimizing the glycoform distribution of Factor VII and Factor VII-related polypeptides. These methods are carried out by the steps of:

10 (a) culturing a cell expressing Factor VII or Factor VII-related polypeptides under a first set of predetermined culture conditions;

 (b) recovering Factor VII or Factor VII-related polypeptides from the culture to obtain a preparation comprising the polypeptides; and

 (c) analyzing the structure of the oligosaccharides linked to the polypeptides to determine a glycoform pattern.

15 The methods may further comprise:

 (d1) altering the culture conditions of step (a) to achieve a second set of predetermined culture conditions;

 (e1) repeating steps (b)-(d1) until a desired glycoform pattern is achieved.

Alternatively, the methods may further comprise

20 (d2) treating the preparation chemically and/or enzymatically to alter the oligosaccharide structure; and

 (e2) repeating steps (b)-(d2) until a desired glycoform pattern is achieved.

These methods may further comprise the step of subjecting preparations having predetermined glycoform patterns to at least one test of bioactivity (including, e.g., clotting,

25 Factor X proteolysis, or TF binding) or other functionality (such as, e.g., pharmacokinetic profile or stability), and correlating particular glycoform patterns with particular bioactivity or functionality profiles in order to identify a desired glycoform pattern.

The variables in the culture conditions that may be altered in step (d1) include, without limitation: the cell of origin, such as, e.g., a cell derived from a different species than originally used; or a mutant or recombinant cell having alterations in one or more glycosyl-transferases or glycosidases or other components of the glycosylation apparatus (see, Grabenhorst et al., *Glycoconjugate J.* 16:81, 1999; Bragonzi et al., *Biochem. Biophys. Acta* 1474:273, 2000; Weikert, *Nature Biotechnol.* 17:1116, 1999); the level of expression of the polypeptide; the metabolic conditions such as, e.g., glucose or glutamine concentration; the absence or presence of serum; the concentration of vitamin K; protein hydrolysates, hor-

mones, trace metals, salts as well as process parameters like temperature, dissolved oxygen level and pH.

The enzymatic treatments that may be used in step (d2) to modify the oligosaccharide pattern of a preparation include, without limitation, treatment with one or more of sialidase (neuraminidase), galactosidase, fucosidase; galactosyl transferase, fucosyl transferase, and/or sialyltransferase, in a sequence and under conditions that achieve a desired modification in the distribution of oligosaccharide chains having particular terminal structures. Glycosyl transferases are commercially available from Calbiochem (La Jolla, CA) and glycosidases are commercially available from Glyko, Inc., (Novato, CA).

In one series of embodiments, host cells expressing Factor VII or a related polypeptide are subjected to specific culture conditions in which they secrete glycosylated Factor VII polypeptides having the desired pattern of oligosaccharide structures described above as any of (i)-(vi). Such culture conditions include, without limitation, a reduction in, or complete absence of, serum. Preferably, the host cells are adapted to grow in the absence of serum and are cultured in the absence of serum both in the growth phase and in the production phase. Such adaptation procedures are described, e.g., in Scharfenberg, et al., *Animal Cell Technology Developments towards the 21st Century*, E. C. Beuvery et al. (Eds.), Kluwer Academic Publishers, pp. 619-623, 1995 (BHK and CHO cells); Cruz, *Biotechnol. Tech.* 11:117-120, 1997 (insect cells); Keen, *Cytotechnol.* 17:203-211, 1995 (myeloma cells); Berg et al., *Biotechniques* 14:972-978, 1993 (human kidney 293 cells). In a preferred embodiment, the growth medium that is added to the cells contains no protein or other component that was isolated from an animal tissue or an animal cell culture. See, e.g., Example 1 below. Typically, in addition to conventional components, a medium suitable for producing Factor VII contains Vitamin K at a concentration between 0.1-50 mg/liter, which is required for γ -carboxylation of glutamine residues in Factor VII.

In another series of embodiments, the glycoforms of the invention are produced by subjecting a preparation of Factor VII or Factor VII-related polypeptides to enzymatic and/or chemical modification of the N-linked oligosaccharides contained therein.

30

Factor VII Preparations

As used herein, a "Factor VII preparation" refers to a plurality of Factor VII polypeptides, Factor VIIa polypeptides, or Factor VII-related polypeptides, including variants and chemically modified forms, that have been separated from the cell in which they were synthesized.

Separation of polypeptides from their cell of origin may be achieved by any method known in the art, including, without limitation, removal of cell culture medium containing the desired product from an adherent cell culture; centrifugation or filtration to remove non-adherent cells; and the like.

5 Optionally, Factor VII polypeptides may be further purified. Purification may be achieved using any method known in the art, including, without limitation, affinity chromatography, such as, e.g., on an anti-Factor VII antibody column (see, e.g., Wakabayashi et al., *J. Biol. Chem.* 261:11097, 1986; and Thim et al., *Biochem.* 27:7785, 1988); hydrophobic interaction chromatography; ion-exchange chromatography; size exclusion chromatography; 10 electrophoretic procedures (e.g., preparative isoelectric focusing (IEF), differential solubility (e.g., ammonium sulfate precipitation), or extraction and the like. See, generally, Scopes, *Protein Purification*, Springer-Verlag, New York, 1982; and *Protein Purification*, J.-C. Janson and Lars Ryden, editors, VCH Publishers, New York, 1989. Following purification, the preparation preferably contains less than about 10% by weight, more preferably less than about 15 5% and most preferably less than about 1%, of non-Factor VII proteins derived from the host cell.

Factor VII and Factor VII-related polypeptides may be activated by proteolytic cleavage, using Factor XIIa or other proteases having trypsin-like specificity, such as, e.g., Factor IXa, kallikrein, Factor Xa, and thrombin. See, e.g., Osterud et al., *Biochem.* 11:2853 (1972); 20 Thomas, U.S. Patent No. 4,456,591; and Hedner et al., *J. Clin. Invest.* 71:1836 (1983). Alternatively, Factor VII may be activated by passing it through an ion-exchange chromatography column, such as Mono Q® (Pharmacia) or the like. The resulting activated Factor VII may then be formulated and administered as described below.

25 ***Functional Properties of Factor VII Preparations***

The preparations of Factor VII polypeptides and Factor VII-related polypeptides having predetermined oligosaccharide patterns according to the invention exhibit improved functional properties relative to reference preparations. The improved functional properties may include, without limitation, a) physical properties such as, e.g., storage 30 stability; b) pharmacokinetic properties such as, e.g., bioavailability and half-life; and c) immunogenicity in humans.

A reference preparation refers to a preparation comprising a polypeptide that is identical to that contained in the preparation of the invention to which it is being compared (such as, e.g., wild-type Factor VII or a particular variant or chemically modified 35 form) except for exhibiting a different pattern of asparagine-linked glycosylation. For

example, reference preparations typically comprise one or more of the following glyco-form patterns: (i) less than about 93% (such as, e.g. less than about 92% or less than about 90%) of the oligosaccharide chains contain at least one sialic acid residue; (ii) at least about 6% (such as, e.g., at least about 7.5% or at least about 10%) of the oligo-saccharide chains lack any sialic acid (i.e., are neutral); (iii) at least about 10% (such as, e.g., at least about 12.5% or at least about 15%) of the oligosaccharide chains contain at least one terminal galactose residue; (iv) at least about 15% (such as, e.g., at least about 20% or at least about 25%) of the oligosaccharide chains contain at least one terminal N-acetylgalactosamine residue; (v) at least about 25% (such as, e.g., at least about 30% or at least about 35%) of the oligosaccharide chains contain at least one uncapped antenna (i.e., contain at least one terminal galactose or N-acetylgalactosamine residue); or (vi) essentially undetectable levels (such as, e.g., less than about 0.2%) of antennary fucose residues.

Storage stability of a Factor VII preparation may be assessed by measuring (a) the time required for 20% of the bioactivity of a preparation to decay when stored as a dry powder at 25°C and/or (b) the time required for a doubling in the proportion of Factor VIIa aggregates in the preparation.

In some embodiments, the preparations of the invention exhibit an increase of at least about 30%, preferably at least about 60% and more preferably at least about 100%, in the time required for 20% of the bioactivity to decay relative to the time required for the same phenomenon in a reference preparation, when both preparations are stored as dry powders at 25°C. Bioactivity measurements may be performed using any of a clotting assay, proteolysis assay, TF-binding assay, or TF-independent thrombin generation assay.

In some embodiments, the preparations of the invention exhibit an increase of at least about 30%, preferably at least about 60%, and more preferably at least about 100%, in the time required for doubling of aggregates relative to a reference preparation, when both preparations are stored as dry powders at 25°C. The content of aggregates is determined by gel permeation HPLC on a Protein Pak 300 SW column (7.5 x 300 mm) (Waters, 80013) as follows. The column is equilibrated with Eluent A (0.2 M ammonium sulfate, 5 % isopropanol, pH adjusted to 2.5 with phosphoric acid, and thereafter pH is adjusted to 7.0 with triethylamine), after which 25 µg of sample is applied to the column. Elution is with Eluent A at a flow rate of 0.5 ml/min for 30 min, and detection is achieved by measuring absorbance at 215 nm. The content of aggregates is calculated as the peak area of the Factor VII aggregates/total area of Factor VII peaks (monomer and aggregates).

“Bioavailability” refers to the proportion of an administered dose of a Factor VII or Factor VII-related preparation that can be detected in plasma at predetermined times after administration. Typically, bioavailability is measured in test animals by administering a dose of between about 25-250 µg/kg of the preparation; obtaining plasma samples at predetermined times after administration; and determining the content of Factor VII or Factor VII-related polypeptides in the samples using one or more of a clotting assay (or any bioassay), an immunoassay, or an equivalent. The data are typically displayed graphically as [Factor VII] v. time and the bioavailability is expressed as the area under the curve (AUC). Relative bioavailability of a test preparation refers to the ratio between the AUC of the test preparation and that of the reference preparation.

In some embodiments, the preparations of the present invention exhibit a relative bioavailability of at least about 110%, preferably at least about 120%, more preferably at least about 130% and most preferably at least about 140% of the bioavailability of a reference preparation. The bioavailability may be measured in any mammalian species, preferably dogs, and the predetermined times used for calculating AUC may encompass different increments from 10 min- 8 h.

“Half-life” refers to the time required for the plasma concentration of Factor VII polypeptides of Factor VII-related polypeptides to decrease from a particular value to half of that value. Half-life may be determined using the same procedure as for bioavailability. In some embodiments, the preparations of the present invention exhibit an increase in half-life of at least about 0.25 h, preferably at least about 0.5 h, more preferably at least about 1 h, and most preferably at least about 2 h, relative to the half-life of a reference preparation.

“Immunogenicity” of a preparation refers to the ability of the preparation, when administered to a human, to elicit a deleterious immune response, whether humoral, cellular, or both. Factor VIIa polypeptides and Factor VIIa-related polypeptides are not known to elicit detectable immune responses in humans. Nonetheless, in any human sub-population, there may exist individuals who exhibit sensitivity to particular administered proteins. Immunogenicity may be measured by quantifying the presence of anti-Factor VII antibodies and/or Factor VII-responsive T-cells in a sensitive individual, using conventional methods known in the art. In some embodiments, the preparations of the present invention exhibit a decrease in immunogenicity in a sensitive individual of at least about 10%, preferably at least about 25%, more preferably at least about 40% and most preferably at least about 50%, relative to the immunogenicity for that individual of a reference preparation.

Pharmaceutical Compositions and Methods of Use

The preparations of the present invention may be used to treat any Factor VII-responsive syndrome, such as, e.g., bleeding disorders, including, without limitation, those caused by clotting factor deficiencies (e.g., haemophilia A and B or deficiency of coagulation factors XI or VII); by thrombocytopenia or von Willebrand's disease, or by clotting factor inhibitors, or excessive bleeding from any cause. The preparations may also be administered to patients in association with surgery or other trauma or to patients receiving anticoagulant therapy.

Preparations comprising Factor VII-related polypeptides according to the invention, which have substantially reduced bioactivity relative to wild-type Factor VII, may be used as anticoagulants, such as, e.g., in patients undergoing angioplasty or other surgical procedures that may increase the risk of thrombosis or occlusion of blood vessels as occurs, e.g., in restenosis. Other medical indications for which anticoagulants are prescribed include, without limitation, deep vein thrombosis, pulmonary embolism, stroke, disseminated intravascular coagulation (DIC), fibrin deposition in lungs and kidneys associated with gram-negative endotoxemia, myocardial infarction; Acute Respiratory Distress Syndrome (ARDS), Systemic Inflammatory Response Syndrome (SIRS), Hemolytic Uremic Syndrome (HUS), MOF, and TTP.

Pharmaceutical compositions comprising the Factor VII and Factor VII-related preparations according to the present are primarily intended for parenteral administration for prophylactic and/or therapeutic treatment. Preferably, the pharmaceutical compositions are administered parenterally, i.e., intravenously, subcutaneously, or intramuscularly. They may be administered by continuous or pulsatile infusion.

Pharmaceutical compositions or formulations comprise a preparation according to the invention in combination with, preferably dissolved in, a pharmaceutically acceptable carrier, preferably an aqueous carrier or diluent. A variety of aqueous carriers may be used, such as water, buffered water, 0.4% saline, 0.3% glycine and the like. The preparations of the invention can also be formulated into liposome preparations for delivery or targeting to the sites of injury. Liposome preparations are generally described in, e.g., U.S. Patents Nos. 4,837,028, 4,501,728, and 4,975,282. The compositions may be sterilised by conventional, well-known sterilisation techniques. The resulting aqueous solutions may be packaged for use or filtered under aseptic conditions and lyophilised, the lyophilised preparation being combined with a sterile aqueous solution prior to administration.

The compositions may contain pharmaceutically acceptable auxiliary substances or adjuvants, including, without limitation, pH adjusting and buffering agents and/or tonicity

adjusting agents, such as, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, etc.

The concentration of Factor VII or Factor VII-related polypeptides in these formulations can vary widely, i.e., from less than about 0.5% by weight, usually at or at least 5 about 1% by weight to as much as 15 or 20% by weight and will be selected primarily by fluid volumes, viscosities, etc., in accordance with the particular mode of administration selected.

Thus, a typical pharmaceutical composition for intravenous infusion could be made up to contain 250 ml of sterile Ringer's solution and .10 mg of the preparation. Actual methods for preparing parenterally administrable compositions will be known or apparent to 10 those skilled in the art and are described in more detail in, for example, *Remington's Pharmaceutical Sciences*, 18th ed., Mack Publishing Company, Easton, PA (1990).

The compositions containing the preparations of the present invention can be administered for prophylactic and/or therapeutic treatments. In therapeutic applications, compositions are administered to a subject already suffering from a disease, as described 15 above, in an amount sufficient to cure, alleviate or partially arrest the disease and its complications. An amount adequate to accomplish this is defined as "therapeutically effective amount". Effective amounts for each purpose will depend on the severity of the disease or injury as well as the weight and general state of the subject. In general, however, the effective amount will range from about 0.05 mg up to about 500 mg of the preparation per 20 day for a 70 kg subject, with dosages of from about 1.0 mg to about 200 mg of the preparation per day being more commonly used. It will be understood that determining an appropriate dosage may be achieved using routine experimentation, by constructing a matrix of values and testing different points in the matrix.

Local delivery of the preparations of the present invention, such as, for 25 example, topical application, may be carried out, e.g., by means of a spray, perfusion, double balloon catheters, stent, incorporated into vascular grafts or stents, hydrogels used to coat balloon catheters, or other well established methods. In any event, the pharmaceutical compositions should provide a quantity of the preparation sufficient to effectively treat the subject.

30 The pharmaceutical compositions of the invention may further comprise other bioactive agents, such as, e.g., non-Factor VII-related coagulants or anticoagulants.

The following examples are intended as non-limiting illustrations of the present invention.

Example 1: Production and Analysis of a Factor VII preparation exhibiting an altered glycoform pattern

The following experiment was performed to produce a Factor VII preparation having an altered glycoform pattern.

5 I. *Production:* A BHK cell line transformed with a Factor VII-encoding plasmid was adapted to growth in suspension culture in the absence of serum. The cells were propagated sequentially in spinner cultures and as the cell number increased, the volume was gradually increased by addition of new medium.

Finally, 6 l of seed culture were inoculated into a 100-liter production bioreactor containing 10 macroporous Cytopore 1 carriers (Pharmacia), after which the suspension cells became immobilized in the carriers. The culture was maintained at 36°C at a pH of 6.7–6.9 and a DO of 50%. The volume in the production bioreactor was gradually increased by addition of new medium as the cell number increased. When the cell density reached approximately 2 x 15 10^6 cells/ml, the production phase was initiated and a medium change was performed every 24 hours: Agitation was stopped to allow for sedimentation of the cell-containing carriers, and 80% of the culture supernatant was then harvested and replaced with new medium. The harvested culture supernatant was filtered to remove non-trapped cells and cell debris and was then transferred for further processing.

During the production phase the cells reached 3–6 20×10^6 cells/ml and a titer of 2–7 mg Factor VII/liter.

II. *Analysis of the glycoform pattern of recombinant Factor VII*

The oligosaccharide patterns of the following preparations were compared: (a) recombinant Factor VII preparations produced as described in part I (n=7); and two reference 25 preparations: (b) recombinant Factor VII preparations produced in BHK cells in the presence of calf serum (n=10); and (c) a Factor VII preparation purified from human plasma.

The N-linked oligosaccharides were released from the polypeptides by chemical cleavage (hydrazinolysis, on a GlycoPrep1000 unit, Oxford GlycoSciences) or by enzymatic 30 cleavage (N-glycosidase F from, eg., Boehringer Mannheim). The released oligosaccharides were labeled with 2-aminobenzamide (using a signal labelling kit, K-404, Oxford GlycoSciences or Glyko). The labeled oligosaccharides were analysed using anion-exchange HPLC on a CarboPac PA100 column (4x250 mm, Dionex, P/N 43055) with a Guard column (4x50 mm, Dionex, P/N 43054). The column was equilibrated with 150 mM sodium hydrox-

ide and eluted with a gradient of 0-150 mM sodium acetate, 150 mM sodium hydroxide. Oligosaccharides were detected using fluorescence, with excitation at 330 nm and emission at 420 nm.

The relative contents of the various Factor VII oligosaccharide structures (Klausen et al., 1998) were calculated as the relative peak areas for the carbohydrate peaks in the anion-exchange HPLC analysis. Based on the structural elements of each oligosaccharide, it was assigned to one of the following: (i) chains containing at least one sialic acid; (ii) chains lacking any sialic acid (i.e., neutral); (iii) chains containing at least one terminal galactose residue; (iv) chains containing at least one terminal N-acetylgalactosamine residue; and (v) chains containing at least one uncapped antenna (i.e., at least one terminal galactose or N-acetylgalactosamine residue). Finally, the sum of the relative contents of the oligosaccharide chains assigned to each group was calculated as a percentage of the total oligosaccharide chains. The standard deviation of this determination was calculated to be 0.08% (intraday variation); 0.7% (day-to-day variation); and 0.5% (1-100 µg interval).

The resulting glycoform patterns are illustrated in the following table:

	(i)	(ii)	(iii)	(iv)	(v)
a	93.1-98.7	1.3-6.9	5.9-16.4	5.9-8.7	11.7-23.9
b	88.3-92.5	7.5-12.9	9.4-16.8	19.0-28.6	30.1-39.0
c	99.5%	<0.5%	2-3%	0%	2-3%

The recombinant Factor VII preparations produced according to this Example (i.e., in the absence of serum) exhibit a glycoform pattern that differs from both the glycoform pattern of recombinant Factor VII produced in the presence of serum and native Factor VII isolated from human plasma. The oligosaccharides of recombinant Factor VII produced in the absence of serum are sialylated to a higher extent than those produced in the presence of serum and contain less neutral chains and less chains that terminate in either galactose or N-acetylgalactosamine.

III. Bioavailability:

The following experiment was performed to compare the bioavailability of two Factor VII preparations produced as above (I and II) with that of two reference Factor VII preparations (i.e., produced in the presence of serum) (A and B).

Groups of 8 rats were administered either a test preparation or a reference preparation at a dose of 25 µg/kg (= 100 µg/rat) in a glycylglycine buffer (pH 7.4) containing sodium chloride (7.87 mg/ml), calcium chloride dihydrate (1.48 mg/ml), mannitol (2.5 mg/ml) and polysorbate 80. Blood samples were withdrawn at 10 min and 30 min following the initial administration. Plasma was obtained from the samples and Factor

VII was quantified by ELISA. Bioavailability of each sample is expressed as the dose-adjusted area under the plasma concentration curve for Factor VII based on the 10 and 30-min samples (AUC_{10-30}/dose). The relative bioavailability is expressed as the ratio between the mean AUC_{10-30}/dose of the test and reference samples X 100. The 90% confidence limits for the relative bioavailability were calculated from the 90% confidence limits for differences between preparations.

The results are summarized in the Table below. (The % sialylation of each preparation, which was measured as described above, is indicated in parentheses).

test	reference	relative bioavailability	90% conf. lower	90% conf. upper
I (97.5%)	A (93%)	128.6	116.1	141.1
I (97.5%)	B (86%)	154.9	141.2	168.5
II (96.7%)	A 93%	117.3	104.8	129.8
II (96.7%)	B (86%)	141.2	127.5	154.8

10

15

The results indicate that even relatively small differences in the proportion of oligosaccharide chains having at least one sialic acid residue, such as, e.g., between 93% and 96 or 97%, can have a marked impact on bioavailability (increase of 20-30%).

20 A 10% increase in the % sialylation, moreover, causes a 40-50% increase in bioavailability.

Example 2: Analysis of Factor VII preparations exhibiting an altered glycoform pattern

Factor VII was produced as described in Example 1 above, with the exception that the Factor VII was harvested from 500-l cultures. Glycoform analysis was performed as described in Example 1. Three independent preparations (A, B, and C) were analyzed and compared with a reference preparation (D).

5 Bioavailability was measured in a dog model as follows: The experiment was performed as a four leg cross-over study in 12 Beagle dogs divided in four groups. All animals received each of the three test preparations A, B, and C and the reference preparation D at a dose of ≈90 µg/kg in a glycylglycine buffer (pH 5.5) containing sodium chloride (2.92 mg/ml), calcium chloride dihydrate (1.47 mg/ml), mannitol (30 mg/ml) and polysorbate 80. Blood
10 samples were withdrawn at 10, 30, and 60 minutes and 2, 3, 4, 6 and 8 hours following the initial administration. Plasma was obtained from the samples and Factor VII was quantified by ELISA.

15 Bioavailability of each sample is expressed as the dose-adjusted area under the plasma concentration curve for Factor VII (AUC/dose). The relative bioavailability is expressed as the ratio between the mean AUC/dose of the test and reference preparation X 100 and 90% confidence limits for the relative bioavailability were calculated.

The results are summarized in the Table below. The % sialylation of each preparation, which was measured as described in Example 1 above, is indicated in parentheses.

20

Test	Reference	Relative bioavailability	90% conf.limit lower	90% conf.limit upper
A (98.7%)	D (88.2%)	144	135	153
B (95.9%)	D (88.2%)	127	119	136
C (93.1%)	D (88.2%)	112	105	120

25 The results indicate that small differences in the proportion of oligosaccharide chains having at least one sialic acid residue have a marked impact on bioavailability of Factor VII. A 10% increase in the % sialylation causes a 30-50% increase in bioavailability with a close to linear relationship for the three test preparations and the reference preparation

Example 3: Factor VII preparations exhibiting an altered glycoform pattern

The following experiment was performed to produce a Factor VII preparation having an altered glycoform pattern.

I. Construction of cell line and Factor VII production:

A plasmid vector pLN174 for expression of human FVII has been described (Persson and Nielsen. 1996. *FEBS Lett.* 385: 241-243). Briefly, it carries the cDNA nucleotide sequence encoding human FVII including the propeptide under the control of a mouse metallothionein promoter for transcription of the inserted cDNA, and mouse dihydrofolate reductase cDNA under the control of an SV40 early promoter for use as a selectable marker.

For construction of a plasmid vector encoding a gamma-carboxylation recognition sequence, a cloning vector (pBluescript II KS+, Stratagene) containing cDNA encoding FVII including its propeptide was used (pLN171). (Persson et al. 1997. *J. Biol. Chem.* 272: 19919-19924). A nucleotide sequence encoding a stop codon was inserted into the cDNA encoding FVII after the propeptide of FVII by inverse PCR-mediated mutagenesis using this cloning vector. The template plasmid was denatured by treatment with NaOH followed by PCR with Pwo (Boehringer-Mannheim) and Taq (Perkin-Elmer) polymerases with the following primers:

15

- a) 5'-AGC GTT TTA GCG CCG GCG CCG GTG CAG GAC-3'
- b) 5'-CGC CGG CGC TAA AAC GCT TTC CTG GAG GAG CTG CGG CC-3'

The resulting mix was digested with DpnI to digest residual template DNA and *Escherichia coli* were transformed with the PCR product. Clones were screened for the presence of the mutation by sequencing. The cDNA from a correct clone was transferred as a BamHI-EcoRI fragment to the expression plasmid pcDNA3 (Invitrogen). The resulting plasmid was termed pLN329. CHO K1 cells (ATCC CCl61) were transfected with equal amounts of pLN174 and pLN329 with the Fugene6 method (Boehringer-Mannheim). Transfectants 20 were selected by the addition of methotrexate to 1 μ M and G-418 to 0.45 mg/ml. The pool of transfectants were cloned by limiting dilution and FVII expression from the clones was measured.

A high producing clone was further subcloned and a clone E11 with a specific FVII expression of 2.4 pg/cell/day in Dulbecco-modified Eagle's medium with 10 % fetal calf serum was selected. The clone was adapted to serum free suspension culture in a commercially available CHO medium (JRH Bioscience) free of animal derived components.

The adapted cells were propagated sequentially in spinner cultures and as the cell number increased, the volume was gradually increased by addition of new medium. After 25 days, 6 l of spinner culture were inoculated into a 50-liter bioreactor. The cells

were propagated in the bioreactor and as the cell number increased, the volume was gradually increased by addition of new medium.

Finally, 50 l of seed culture were inoculated into a 500-liter production bioreactor containing macroporous Cytopore 1 carriers (Pharmacia), after which the suspension cells became immobilized in the carriers. The culture was maintained at 36°C at a pH of 7.0-7.1 and a Dissolved Oxygen Tension (DOT) of 50% of saturation. The volume in the bioreactor was gradually increased by addition of new medium as the cell number increased. When the cell density reached approximately $10-12 \times 10^5$ cells/ml, the production phase was initiated and a medium change was performed every 24 hours: agitation was stopped to allow for sedimentation of the cell-containing carriers, and 80% of the culture supernatant was then harvested and replaced with new medium. The harvested culture supernatant was filtered to remove non-trapped cells (i.e. cells that were not immobilized in carriers) and cell debris and was then transferred for further processing.

During the production phase the cells reached $2-3 \times 10^7$ cells/ml and a titer of 8 mg Factor VII/liter.

II. Glycoform Analysis:

A. The oligosaccharide pattern of a Factor VII preparation produced as described above (a) was compared with those of (b) recombinant Factor VII preparations produced in BHK cells in the presence of calf serum and (c) a Factor VII preparation purified from human plasma. The methods used were essentially as described in Example 1.

The results are shown in the Table below. The oligosaccharide assignments are as follows: (i) chains containing at least one sialic acid; (ii) chains lacking any sialic acid (i.e., neutral); (iii) chains containing at least one terminal galactose residue; (iv) chains containing at least one terminal N-acetylgalactosamine residue; and (v) chains containing at least one uncapped antenna (i.e., at least one terminal galactose or N-acetylgalactosamine residue).

30

	(i)	(ii)	(iii)	(iv)	(v)
a	95.2	4.8	22.9	0.1	23.0
b	88.3-92.5	7.5-12.9	9.4-16.8	19.0-28.6	30.1-39.0
c	99.5%	<0.5%	2-3%	0%	2-3%

B. The oligosaccharide patterns of five independent Factor VII preparations produced as described in this Example (a) were compared with those of (b) recombinant Factor VII preparations produced in BHK cells in the presence of calf serum and (c) a Factor VII preparation purified from human plasma, using the analytical methods 5 described in Example 1.

Based on the structural elements of each oligosaccharide, it was assigned to one of the following: (i) chains containing at least one sialic acid; (ii) chains lacking any sialic acid (i.e., neutral); (iii) chains containing at least one fucose linked to the antenna. Finally, the sum of the relative contents of the oligosaccharide chains assigned to each group was calculated as a percentage of the total oligosaccharide chains. The standard deviation of this determination was calculated to be 0.08% (intraday variation); 0.7% (day-to-day variation); and 10 0.5% (1-100 µg interval).

The resulting glycoform patterns are illustrated in the following Table:

	(i)	(ii)	(iii)
a	89.0-97.9%	2.1-11.0%	6.3-21.3%
b	88.3-92.5%	7.5-12.9%	0%
c	99.5%	<0.5%	0%

15

The recombinant Factor VII preparations produced according to Example 1 (i.e., produced in the absence of serum by the CHO cell line) exhibit a glycoform pattern that differs from both the glycoform pattern of recombinant Factor VII produced in the presence of serum and native Factor VII isolated from human plasma. The oligosaccharides of recombinant Factor VII produced in the absence of serum by the CHO 20 282.4 cell line include structures with fucose linked to the antenna, which are absent from both of the reference preparations. Two of the structures have been purified and characterized by matrix assisted laser desorption ionisation mass spectrometry, by treatment with linkage specific fucosidase enzymes and by anion-exchange HPLC as 25 described above. The two structures have been shown to contain the sialyl Lewis x structure, i.e., fucose linked α 1->3 to an antennary N-acetylglucosamine in a sialylated oligosaccharide.

III. Bioactivity:

30 Five Factor VII preparations produced as described in this Example were analyzed for (a) thrombin generation and (b) binding to tissue factor (TF) and compared

with recombinant Factor VII produced in BHK cells in the presence of serum (reference). The following Table correlates the glycoform patterns (% of oligosaccharide chains containing sialic acid and the % containing fucosylated antenna) and the two bioactivities.

5

Factor VII Preparation	Oligosaccharide Pattern		Thrombin generation (% of reference)	TF binding Kd (nM)
	% Sialyl	% Fucosyl		
1	98	6	125	2.8
2	94	13	123	2.0
3	93	14	126	1.8
4	88	16	145	3.3
5	86	21	158	2.8
reference	86-93	0	100	2.2-6.6

The results indicate that Factor VII preparations having fucosylated antennae exhibit higher TF-independent Factor VII activity (as exhibited, e.g. by thrombin generation) than Factor VII preparations lacking fucosylated antennae.

10

Example 4: In Vitro Hydrolysis Assay

The following method can be used to assay Factor VIIa bioactivity. The assay is carried out in a microtiter plate (MaxiSorp, Nunc, Denmark). The chromogenic substrate D-Ile-Pro-Arg-p-nitroanilide (S-2288, Chromogenix, Sweden), at a final concentration of 1 mM, is added to Factor VIIa (final concentration 100 nM) in 50 mM Hepes, pH 7.4, containing 0.1 M NaCl, 5 mM CaCl₂ and 1 mg/ml bovine serum albumin. The absorbance at 405 nm is measured continuously in a SpectraMax™ 340 plate reader (Molecular Devices, USA). The absorbance developed during a 20-minute incubation, after subtraction of the absorbance in a blank well containing no enzyme, is used to calculate the ratio between the activities of a test and a reference Factor VIIa.

Example 5: In Vitro Proteolysis Assay

The following method can be used to assay Factor VIIa bioactivity. The assay is carried out in a microtiter plate (MaxiSorp, Nunc, Denmark). Factor VIIa (10 nM) and Factor X (0.8 microM) in 100 µl 50 mM Hepes, pH 7.4, containing 0.1 M NaCl, 5 mM CaCl₂ and 1 mg/ml bovine serum albumin, are incubated for 15 min. Factor X cleavage is then stopped

by the addition of 50 μ l 50 mM Hepes, pH 7.4, containing 0.1 M NaCl, 20 mM EDTA and 1 mg/ml bovine serum albumin. The amount of Factor Xa generated is measured by addition of the chromogenic substrate Z-D-Arg-Gly-Arg-*p*-nitroanilide (S-2765, Chromogenix, Sweden), final concentration 0.5 mM. The absorbance at 405 nm is measured continuously in a 5 SpectraMax™ 340 plate reader (Molecular Devices, USA). The absorbance developed during 10 minutes, after subtraction of the absorbance in a blank well containing no FVIIa, is used to calculate the ratio between the proteolytic activities of a test and a reference Factor VIIa.

10

All patents, patent applications, and literature references referred to herein are hereby incorporated by reference in their entirety.

Many variations of the present invention will suggest themselves to those skilled in the art in light of the above detailed description. Such obvious variations are within the full 15 intended scope of the appended claims.

Claims:

1. A preparation comprising a plurality of Factor VII polypeptides or Factor VII-related polypeptides, wherein the polypeptides comprise asparagine-linked oligosaccharide chains and wherein between about 94-99% of the oligosaccharide chains comprise at least one sialic acid moiety.
5
2. A preparation comprising a plurality of Factor VII polypeptides or Factor VII-related polypeptides, wherein the polypeptides comprise asparagine-linked oligosaccharide chains and wherein between about 1-7% of the oligosaccharide chains have a neutral charge.
10
3. A preparation comprising a plurality of Factor VII polypeptides or Factor VII-related polypeptides, wherein the polypeptides comprise asparagine-linked oligosaccharide chains and wherein between about 6-16% of the oligosaccharide chains comprise at least one terminal galactose residue.
15
4. A preparation comprising a plurality of Factor VII polypeptides or Factor VII-related polypeptides, wherein the polypeptides comprise asparagine-linked oligosaccharide chains and wherein between about 6-9% of the oligosaccharide chains comprise at least one terminal N-acetylgalactosamine residue.
20
5. A preparation comprising a plurality of Factor VII polypeptides or Factor VII-related polypeptides, wherein the polypeptides comprise asparagine-linked oligosaccharide chains and wherein between about 11-23% of the oligosaccharide chains comprise at least one terminal galactose or N-acetylgalactosamine residue.
25
6. A preparation comprising a plurality of Factor VII polypeptides or Factor VII-related polypeptides, wherein the polypeptides comprise asparagine-linked oligosaccharide chains and wherein at least about 2% of the oligosaccharide chains comprise at least one fucose moiety linked α 1->3 to an antennary N-acetylglucosamine.
30
7. A preparation as defined in any of claims 1-6, wherein the sialic residues in the oligosaccharide chains are linked to galactose via an α 2->3 linkage.

8. A preparation as defined in any of claims 1-7, wherein the sialic acid residues comprise N-acetylneuraminic acid (Neu5Ac) and N-glycolylneuraminic acid (Neu5Gc).
9. A preparation as defined in any of claims 1-8, wherein the oligosaccharides comprise
5 fucose linked α 1->6 to a core N-acetylglucosamine.
10. A preparation as defined in any of claims 1-9, wherein between about 95-98% of the oligosaccharide chains contain at least one sialic acid residue.
- 10 11. A preparation as defined in any of claims 1-10, wherein between about 96-97% of the oligosaccharide chains contain at least one sialic acid residue.
12. A preparation as defined in any of claims 1-11, wherein between about 2-4% of the oligosaccharide chains have a neutral charge.
- 15 13. A preparation as defined in any of claims 1-12, wherein between about 8-12% of the oligosaccharide chains contain at least one terminal galactose residue.
14. A preparation as defined in any of claims 1-13, wherein between about 7-8% of the oligosaccharide chains contain at least one terminal N-acetylgalactosamine residue.
- 20 15. A preparation as defined in any of claims 1-14, wherein between about 12-18% of the oligosaccharide chains contain at least one terminal galactose or N-acetylgalactosamine residue.
- 25 16. A preparation as defined in any of claims 1-15, wherein at least about 5% of the oligosaccharide chains comprise at least one fucose moiety linked α 1->3 to an antennary N-acetylglucosamine.
- 30 17. A preparation as defined in any of claims 1-16, wherein at least about 10% of the oligosaccharide chains comprise at least one fucose moiety linked α 1->3 to an antennary N-acetylglucosamine.

18. A preparation as defined in any of claims 1-17, wherein at least about 20% of the oligo-saccharide chains comprise at least one fucose moiety linked α 1->3 to an antennary N-acetylglucosamine.
- 5 19. A preparation as defined in any of claims 1-18, wherein at least about 40% of the oligo-saccharide chains comprise at least one fucose moiety linked α 1->3 to an antennary N-acetylglucosamine
- 10 20. A preparation as defined in any of claims 1-19, wherein the polypeptides have the amino acid sequence of wild-type Factor VII.
21. A preparation as defined in any of claims 1-20, wherein the polypeptides are wild-type Factor VIIa.
- 15 22. A preparation as defined in any of claims 1-19, wherein the Factor VII polypeptides are selected from the group consisting of: S52A-Factor VII, S60A-Factor VII, Factor VII that has been proteolytically cleaved between residues 290 and 291; Factor VII that has been proteolytically cleaved between residues 315 and 316; and Factor VII that has been oxidized.
- 20 23. A preparation as defined in any of claims 1-19, wherein the Factor VII-related polypeptides are selected from the group consisting of: R152E-Factor VII, S344A-Factor VII, FFR-Factor VII, and Factor VIIa lacking the Gla domain.
- 25 24. A preparation comprising a plurality of Factor VII polypeptides or Factor VII-related polypeptides, wherein the polypeptides comprise asparagine-linked oligosaccharide chains and wherein (i) between about 94-100% of the oligosaccharide chains comprise at least one sialic acid moiety and (ii) between about 6-9% of the oligosaccharide chains comprise at least one terminal N-acetylgalactosamine residue.
- 30 25. A preparation as defined in claim 24, wherein the Factor VII polypeptides have the sequence of wild-type Factor VII.
- 35 26. A preparation comprising a plurality of Factor VIIa polypeptides having the sequence of wild-type Factor VII, wherein the polypeptides comprise asparagine-linked oligosaccharide

chains and wherein between about 94-99% of the oligosaccharide chains comprise at least one sialic acid residue.

27. A preparation comprising a plurality of Factor VIIa polypeptides having the sequence of wild-type Factor VII, wherein the polypeptides comprise asparagine-linked oligosaccharide chains and wherein at least about 2% of the oligosaccharide chains comprise at least one fucose moiety linked α 1->3 to an antennary N-acetylglucosamine.
28. A preparation as defined in any of claims 1-27, wherein the polypeptides are produced in a host cell selected from the group consisting of fungal, insect, and vertebrate cells.
29. A preparation as defined in claim 28, wherein the host cell is a mammalian cell.
30. A preparation as defined in claim 29, wherein the mammalian cell is derived from a hamster.
31. A preparation as defined in claim 30, wherein the hamster cell is selected from the group consisting of CHO cells and BHK cells.
32. A preparation as defined in claim 29, wherein the mammalian cell is derived from a human.
33. A preparation as defined in claim 32, wherein the human cell is an HEK cell.
34. A preparation as defined in any of claims 1-33, wherein the preparation exhibits a bioavailability that is at least about 110% of the bioavailability of a reference preparation, wherein about 93% or less of the oligosaccharide chains in the reference preparation comprise at least one sialic acid moiety.
35. A preparation as defined in claim 34, wherein the preparation exhibits a bioavailability that is at least about 120% of the bioavailability of the reference preparation.
36. A preparation as defined in claim 35, wherein the preparation exhibits a bioavailability that is at least about 130% of the bioavailability of the reference preparation.

37. A preparation as defined in claim 36, wherein the preparation exhibits a bioavailability that is at least about 140% of the bioavailability of the reference preparation.

38. A method for determining the glycoform pattern of Factor VII and Factor VII-related polypeptides, the method comprising:

(a) culturing a cell expressing Factor VII or Factor VII-related polypeptides under a first set of predetermined culture conditions;

(b) recovering Factor VII or Factor VII-related polypeptides from the culture to obtain a preparation comprising the polypeptides; and

(c) analyzing the structure of the oligosaccharides linked to the polypeptides to determine the glycoform pattern of the preparation.

39. A method as defined in claim 38, further comprising

(d1) altering the culture conditions of step (a) to achieve a second set of predetermined culture conditions;

(e1) repeating steps (b)-(d1) until a desired glycoform pattern is achieved.

40. A method as defined in claim 38, further comprising:

(d2) treating the preparation chemically or enzymatically to alter the oligosaccharide structure; and

(e2) repeating steps (b)-(d2) until a desired glycoform pattern is achieved.

41. A method for producing a preparation comprising Factor VII polypeptides or Factor VII-related polypeptides having a predetermined pattern of N-linked glycosylation, said method comprising culturing a cell expressing the polypeptides under conditions in which at least about 94% of the asparagine-linked oligosaccharides present on the polypeptides comprise at least one sialic acid residue.

42. A pharmaceutical formulation comprising a preparation as defined in any of claims 1-37 and a pharmaceutically acceptable carrier or adjuvant.

43. A method for treating a Factor VII-responsive syndrome, the method comprising administering a pharmaceutical formulation as defined in claim 42 to a patient in need of such treatment, under conditions that result in a decrease in bleeding and/or an increase in blood clotting, wherein the formulation comprises Factor VII polypeptides.

44. A method as defined in claim 43, wherein the syndrome is selected from the group consisting of haemophilia A, haemophilia B, Factor XI deficiency, Factor VII deficiency, thrombocytopenia, von Willebrand's disease, presence of a clotting factor inhibitor, surgery, trauma,
5 and anticoagulant therapy.
45. A method for preventing unwanted bleeding, the method comprising administering a pharmaceutical formulation as defined in claim 42 to a patient in need of such treatment, under conditions that result in a decrease in bleeding and/or an increase in blood clotting,
10 wherein the formulation comprises Factor VII polypeptides.
46. A method for preventing unwanted blood clotting, the method comprising administering a pharmaceutical formulation as defined in claim 42 to a patient in need of such treatment, under conditions effective for inhibiting coagulation, wherein the formulation comprises Factor
15 VII-related polypeptides.
47. A method for preventing tissue factor mediated reactions, the method comprising administering a pharmaceutical formulation as defined in claim 42 to a patient in need of such
20 treatment, under conditions effective for inhibiting coagulation, wherein the formulation comprises Factor VII-related polypeptides.
48. A method as defined in claim 46, wherein the unwanted blood clotting is associated with a condition selected from the group consisting of: angioplasty, deep vein thrombosis,
25 pulmonary embolism, stroke, disseminated intravascular coagulation (DIC), fibrin deposition in lungs and kidneys associated with gram-negative endotoxemia, and myocardial infarction.
49. A method as defined in claim 47, wherein the tissue factor mediated reactions are asosicated with a condition selected from the group consisting of SIRS, ARDS, MOF,HUS,
30 and TTP.
50. Use of a preparation comprising Factor VII polypeptides or Factor VII-related polypeptides as defined in any of claims 1-37 for the preparation of a medicament for treating a Factor VII-responsive syndrome.

51. Use as defined in claim 50, wherein the syndrome is selected from the group consisting of haemophilia A, haemophilia B, Factor XI deficiency, Factor VII deficiency, thrombocytopenia, von Willebrand's disease, presence of a clotting factor inhibitor, surgery, trauma, and anticoagulant therapy.

5

52. Use of a preparation comprising Factor VII polypeptides or Factor VII-related polypeptides as defined in any of claims 1-37 for the preparation of a medicament for prevention of unwanted bleeding.

10 53. Use of a preparation comprising Factor VII polypeptides or Factor VII-related polypeptides as defined in any of claims 1-37 for the preparation of a medicament for prevention of unwanted blood clotting.

15 54. Use as defined in claim 53, wherein the unwanted blood clotting is associated with a condition selected from the group consisting of: angioplasty, deep vein thrombosis, pulmonary embolism, stroke, disseminated intravascular coagulation (DIC), fibrin deposition in lungs and kidneys associated with gram-negative endotoxemia, and myocardial infarction.

20 55. Use of a preparation comprising Factor VII polypeptides or Factor VII-related polypeptides as defined in any of claims 1-37 for the preparation of a medicament for preventing tissue factor-mediated reactions.

25 56. Use as defined in claim 55, wherein the tissue factor mediated reactions are associated with a condition selected from the group consisting of SIRS, ARDS, MOF, HUS, and TTP.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 April 2002 (11.04.2002)

PCT

(10) International Publication Number
WO 02/029025 A3

(51) International Patent Classification⁷: **C12N 9/64,**
A61K 38/36, C12P 21/02, G01N 33/86

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA,
ZW.

(21) International Application Number: PCT/DK01/00633

(22) International Filing Date: 2 October 2001 (02.10.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

PA 2000 01456	2 October 2000 (02.10.2000)	DK
60/238,944	10 October 2000 (10.10.2000)	US
PA 2001 00262	16 February 2001 (16.02.2001)	DK
60/271,581	26 February 2001 (26.02.2001)	US
PA 2001 00430	14 March 2001 (14.03.2001)	DK
60/276,322	16 March 2001 (16.03.2001)	US
PA 2001 00751	14 May 2001 (14.05.2001)	DK

(71) Applicant: NOVO NORDISK A/S [DK/DK]; Novo Allé,
DK-2880 Bagsværd (DK).

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).

(72) Inventors: PINGEL, Hans, Kurt; Munkhøjvænge 35,
DK-3520 Farum (DK). KLAUSEN, Niels, Kristian;
Sassvej 14, DK-2820 Gentofte (DK).


(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:
10 October 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 02/029025 A3

(54) Title: FACTOR VII GLYCOFORMS

(57) Abstract: The present invention relates to compositions comprising Factor VII and other blood clotting factors having altered patterns of asparagine-linked glycosylation.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/DK 01/00633

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12N9/64 A61K38/36 C12P21/02 G01N33/86

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C12P C07K A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

WPI Data, EPO-Internal, PAJ, BIOSIS, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>KEMBALL-COOK G ET AL.: "High-level production of human blood coagulation factors VII and XI using a new mammalian expression vector." GENE (AMSTERDAM), vol. 139, no. 2, 1994, pages 275-279, XP002203071 ISSN: 0378-1119 abstract page 277, left-hand column, line 3 -page 278, right-hand column, line 9 table 1 figure 2</p> <p>-----</p> <p style="text-align: center;">-/--</p>	1-56

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the International filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the International filing date but later than the priority date claimed

T later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

11 July 2002

Date of mailing of the International search report

29/07/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel: (+31-70) 340-2040, Tx. 31 651 epo nl
Fax: (+31-70) 340-3016

Authorized officer

van de Kamp, M

INTERNATIONAL SEARCH REPORT

International Application No
PCT/DK 01/00633

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	KLAUSEN N K ET AL.: "Analysis of the site-specific asparagine-linked glycosylation of recombinant human coagulation factor VIIa by glycosidase digestions, liquid chromatography, and mass spectroscopy." MOLECULAR BIOTECHNOLOGY, vol. 9, no. 3, June 1998 (1998-06), pages 195-204, XP008005265 ISSN: 1073-6085 cited in the application abstract ---	1-56
Y	KLAUSEN N K ET AL.: "Analysis of the glycoforms of human recombinant factor VIIa by capillary electrophoresis and high-performance liquid chromatography" JOURNAL OF CHROMATOGRAPHY A,, vol. 718, no. 1, 1 December 1995 (1995-12-01), pages 195-202, XP004038516 ISSN: 0021-9673 cited in the application abstract ---	1-56
Y	WEBER P L ET AL.: "Characterization of glycopeptides from recombinant coagulation factor VIIa by high-performance liquid chromatography and capillary zone electrophoresis using ultraviolet and pulsed electrochemical detection." ANALYTICAL BIOCHEMISTRY, vol. 225, no. 1, 1995, pages 135-142, XP002203677 ISSN: 0003-2697 cited in the application abstract ---	1-56
Y	THIM L ET AL.: "Amino acid sequence and posttranslational modifications of human factor VII-a from plasma and transfected baby hamster kidney cells" BIOCHEMISTRY, vol. 27, no. 20, 1988, pages 7785-7793, XP002203678 ISSN: 0006-2960 abstract page 7791, right-hand column, line 3 -page 7792, right-hand column, line 16 ---	1-56

-/-

INTERNATIONAL SEARCH REPORT

International Application No PCT/DK 01/00633

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	BJOERN S ET AL.: "Human plasma and recombinant factor VII. Characterization of O-glycosylations at serine residues 52 and 60 and effects of site-directed mutagenesis of serine 52 to alanine" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 266, no. 17, 1991, pages 11051-11057, XP002203679 ISSN: 0021-9258 abstract	1-56
Y	US 6 100 061 A (MUNDT WOLFGANG ET AL) 8 August 2000 (2000-08-08) the whole document column 4, line 32-47	1-56
Y	WO 00 28065 A (WIBERG FINN C ;NOVONORDISK AS (DK); WOELDIKE HELLE (DK); NIELSEN L) 18 May 2000 (2000-05-18) page 4, line 1-16	1-56
Y	US 4 784 950 A (HAGEN FREDERICK S ET AL) 15 November 1988 (1988-11-15) cited in the application column 2, line 59 -column 5, line 2 example 6	1-56
Y	US 5 580 560 A (NICOLAISEN ELSE M ET AL) 3 December 1996 (1996-12-03) cited in the application column 3, line 45 -column 6, line 24	1-56
Y	GOUDEMARD J: "Le facteur VII activé recombinant: un nouveau traitement de l'hémophilie" TRANSFUSION CLINIQUE ET BIOLOGIQUE, vol. 5, no. 4, August 1998 (1998-08), pages 260-265, XP001041135 ISSN: 1246-7820 abstract	1-56
Y	RODDIE P H ET AL.: "Recombinant coagulation factors" BLOOD REVIEWS, vol. 11, no. 4, December 1997 (1997-12), pages 169-177, XP001041136 abstract page 176, line 8 -page 177, line 13	1-56
		-/-

INTERNATIONAL SEARCH REPORT

International Application No
PCT/DK 01/00633

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	GAWLITZEK M ET AL.: "Characterization of changes in the glycosylation pattern of recombinant proteins from BHK-21 cells due to different culture conditions" JOURNAL OF BIOTECHNOLOGY, vol. 42, no. 2, 29 September 1995 (1995-09-29), pages 117-131, XP004036908 ISSN: 0168-1656 abstract page 118, left-hand column, line 1 -page 119, left-hand column, line 17 page 129, left-hand column, line 13 -right-hand column, line 12 ---	1-56
Y	BROAD D ET AL.: "Production of recombinant proteins in serum-free media" CYTOTECHNOLOGY, vol. 5, no. 1, 1991, pages 47-55, XP001073869 the whole document ---	1-56
Y	GRABENHORST E ET AL.: "Genetic engineering of recombinant glycoproteins and the glycosylation pathway in mammalian host cells." GLYCOCONJUGATE JOURNAL., vol. 16, no. 2, February 1999 (1999-02), pages 81-97, XP008005300 ISSN: 0282-0080 cited in the application abstract ---	1-56
Y	WEIKERT S ET AL.: "Engineering Chinese hamster ovary cells to maximize sialic acid content of recombinant glycoproteins." NATURE BIOTECHNOLOGY, vol. 17, no. 11, November 1999 (1999-11), pages 1116-1121, XP002203703 ISSN: 1087-0156 cited in the application abstract page 1116, left-hand column, line 1 -right-hand column, line 24 page 1119, right-hand column, line 27 -page 1120, left-hand column, line 65 ---	1-56

-/-

INTERNATIONAL SEARCH REPORT

International Application No

PCT/DK 01/00633

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>BRAGONZI A ET AL.: "A new Chinese hamster ovary cell line expressing alpha2,6-sialyltransferase used as universal host for the production of human-like sialylated recombinant glycoproteins." <i>BIOCHIMICA ET BIOPHYSICA ACTA</i>, vol. 1474, no. 3, 1 May 2000 (2000-05-01), pages 273-282, XP002203704 ISSN: 0006-3002 cited in the application abstract</p> <p>---</p>	1-56
T	<p>JURLANDER B ET AL.: "Recombinant activated factor VII (rFVIIa): Characterization, manufacturing, and clinical development." <i>SEMINARS IN THROMBOSIS AND HEMOSTASIS</i>, vol. 27, no. 4, August 2001 (2001-08), pages 373-384, XP008005254 ISSN: 0094-6176 the whole document</p> <p>-----</p>	

INTERNATIONAL SEARCH REPORT

International application No.
PCT/DK 01/00633

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 43–49 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/DK 01/00633

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
US 6100061	A	08-08-2000	AT	407255 B 107397 A	26-02-2001 15-06-2000
WO 0028065	A	18-05-2000	AU WO EP US	1262900 A 0028065 A1 1127154 A1 6329176 B1	29-05-2000 18-05-2000 29-08-2001 11-12-2001
US 4784950	A	15-11-1988	AT AU AU CN DE DE DK EP ES ES FI GR HU HU IE JP JP JP JP JP JP JP JP JP JP JP JP LU NO NZ PT RU ZA	92105 T 603983 B2 5617786 A 86102644 A ,B 3688760 D1 3688760 T2 177386 A 0200421 A2 554038 D0 8800343 A1 861598 A 860984 A1 43634 A2 204556 B 61982 B 2107600 C 8024587 B 62000283 A 2835038 B2 10117787 A 2726806 B2 7163374 A 2544090 B2 7163375 A 88806 A9 175066 B 215842 A 82408 A ,B 2122583 C1 8602768 A	15-08-1993 06-12-1990 06-11-1986 03-06-1987 02-09-1993 28-10-1993 18-10-1986 05-11-1986 01-11-1987 01-01-1988 18-10-1986 18-08-1986 30-11-1987 28-01-1992 14-12-1994 06-11-1996 13-03-1996 06-01-1987 14-12-1998 12-05-1998 11-03-1998 27-06-1995 16-10-1996 27-06-1995 03-01-1997 16-05-1994 29-04-1988 01-05-1986 27-11-1998 30-12-1986
US 5580560	A	03-12-1996		NONE	

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 April 2002 (11.04.2002)

PCT

(10) International Publication Number
WO 02/029025 A3

- (51) International Patent Classification⁷: C12N 9/64,
A61K 38/36, C12P 21/02, G01N 33/86
- (21) International Application Number: PCT/DK01/00633
- (22) International Filing Date: 2 October 2001 (02.10.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
- | | | |
|---------------|-------------------------------|----|
| PA 2000 01456 | 2 October 2000 (02.10.2000) | DK |
| 60/238,944 | 10 October 2000 (10.10.2000) | US |
| PA 2001 00262 | 16 February 2001 (16.02.2001) | DK |
| 60/271,581 | 26 February 2001 (26.02.2001) | US |
| PA 2001 00430 | 14 March 2001 (14.03.2001) | DK |
| 60/276,322 | 16 March 2001 (16.03.2001) | US |
| PA 2001 00751 | 14 May 2001 (14.05.2001) | DK |
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (48) Date of publication of this corrected version:
15 May 2003
- (71) Applicant: NOVO NORDISK A/S [DK/DK]; Novo Allé,
DK-2880 Bagsværd (DK).
- (72) Inventors: PINGEL, Hans, Kurt; Munkehøjvænge 35,
DK-3520 Farum (DK). KLAUSEN, Niels, Kristian;
Sassvej 14, DK-2820 Gentofte (DK).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
- (48) Published:
— with international search report
- (88) Date of publication of the international search report:
10 October 2002
- (15) Information about Correction:
see PCT Gazette No. 20/2003 of 15 May 2003, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/029025 A3

(54) Title: FACTOR VII GLYCOFORMS

(57) Abstract: The present invention relates to compositions comprising Factor VII and other blood clotting factors having altered patterns of asparagine-linked glycosylation.

FACTOR VII GLYCOFORMS

Field of the Invention

5 The present invention relates to compositions comprising Factor VII and other blood clotting factors having altered patterns of asparagine-linked glycosylation.

Background of the Invention

10 The proteins involved in the clotting cascade, including, e.g., Factor VII, Factor VIII, Factor IX, Factor X, and Protein C, are proving to be useful therapeutic agents to treat a variety of pathological conditions. Accordingly, there is an increasing need for formulations comprising these proteins that are pharmaceutically acceptable and exhibit a uniform and predetermined clinical efficacy.

15 Because of the many disadvantages of using human plasma as a source of pharmaceutical products, it is preferred to produce these proteins in recombinant systems. The clotting proteins, however, are subject to a variety of co- and post-translational modifications, including, e.g., asparagine-linked (N-linked) glycosylation; O-linked glycosylation; and γ -carboxylation of glu residues. These modifications may be qualitatively or quantitatively different when heterologous cells are used as hosts for 20 large-scale production of the proteins. In particular, production in heterologous cells often results in a different array of glycoforms, which are identical polypeptides having different covalently linked oligosaccharide structures.

25 In different systems, variations in the oligosaccharide structure of therapeutic proteins have been linked to, *inter alia*, changes in immunogenicity and *in vivo* clearance. Thus, there is a need in the art for compositions and methods that provide clotting protein preparations, particularly preparations comprising recombinant human Factor VII, modified Factor VII, or Factor VII-related polypeptides, that contain predetermined glycoform patterns.

Summary of the Invention

30 The present invention relates to preparations comprising Factor VII polypeptides or Factor VII-related polypeptides that exhibit predetermined glycoform patterns. As used herein, a Factor VII or Factor VII-related preparation refers to a plurality of Factor VII or Factor VII-related polypeptides, including variants and chemically modified forms, as well as forms that have been proteolytically activated (e.g., Factor VIIa), that have 35 been separated from the cell in which they were synthesized. A glycoform pattern refers to the distribution within the preparation of oligosaccharide chains having varying

structures that are covalently linked to Factor VII polypeptides or Factor VII-related polypeptides.

In one aspect, the invention provides a preparation comprising a plurality of Factor VII polypeptides or Factor VII-related polypeptides, wherein the polypeptides comprise asparagine-linked oligosaccharide chains and wherein one or more of the following applies: (i) between about 94-100% of the oligosaccharide chains comprise at least one sialic acid moiety; (ii) between about 0-7% of the oligosaccharide chains have a neutral charge; (iii) less than about 16%, such as, e.g., between about 6-16% of the oligosaccharide chains comprise at least one terminal galactose residue; (iv) less than about 25%, such as, e.g., between about 6-9% of the oligosaccharide chains comprise at least one terminal N-acetylgalactosamine residue; or (v) less than about 30%, such as, e.g., between about 11-23% of the oligosaccharide chains comprise at least one terminal galactose or N-acetylgalactosamine residue. In some embodiments, in addition to one or more of (i)-(v): all of the sialic acid residues in the oligosaccharide chains are linked to galactose via an α 2->3 linkage; at least some of the sialic acid residues comprise N-glycolylneuraminic acid (Neu5Gc) in addition to N-acetylneuraminic acid (Neu5Ac); and/or the oligosaccharide chains comprise fucose residues linked α 1->6 to a core N-acetylglucosamine. In one embodiment, the invention encompasses a preparation comprising wild-type Factor VIIa in which between about 94-100% of the oligosaccharide chains have at least one sialic acid residue and all of the sialic acid residues are linked to galactose via an α 2->3 linkage. In another embodiment, the invention encompasses a preparation comprising wild-type Factor VIIa in which between about 94-100% of the oligosaccharide chains have at least one sialic acid residue and at least some of the sialic acid residues are N-glycolylneuraminic acid. In yet another embodiment, the invention encompasses a preparation comprising wild-type Factor VIIa in which between about 94-100% of the oligosaccharide chains have at least one sialic acid residue and at least some of the chains contain N-acetylgalactosamine. The preparations of the present invention thus do not encompass wild-type Factor VII or Factor VIIa that has been isolated from human plasma and has not been modified *ex vivo* by glycosidase treatment.

In another aspect, the invention provides a preparation comprising a plurality of Factor VII polypeptides or Factor VII-related polypeptides, wherein the polypeptides comprise asparagine-linked oligosaccharide chains and wherein at least about 2% of the oligosaccharide chains contain at least one fucose linked α 1->3 to an antennary N-acetylglucosamine residue (i.e., an N-acetylglucosamine residue that is linked β 1->2,4,

or 6 to a Man residue). Preferably, at least about 5% of the oligosaccharide chains contain at least one such antennary fucose residue; more preferably, at least about 10% or 20%; and most preferably, at least about 40%.

The preparations according to invention may comprise one or more of unmodified wild-type Factor VII; wild-type Factor VII that has been subjected to chemical and/or enzymatic modification; and Factor VII variants having one or more alterations in amino acid sequence relative to wild-type Factor VII. The preparations of the invention may be derived from human cells expressing Factor VII from an endogenous Factor VII gene or from cells programmed to express Factor VII or a Factor VII-related polypeptide~~s~~ from a recombinant gene.

In another aspect, the invention provides preparations comprising Factor VII or Factor VII-related polypeptides that exhibit one or more improved functional properties, including, without limitation, increased storage stability, bioavailability, and/or half-life.

In another aspect, the invention encompasses methods for determining and/or optimizing the glycoform pattern of Factor VII and Factor VII-related polypeptides, which are carried out by the steps of:

- (a) culturing a cell expressing Factor VII or Factor VII-related polypeptides under a first set of predetermined culture conditions;
- (b) recovering Factor VII or Factor VII-related polypeptides from the culture to obtain a preparation comprising the polypeptides; and
- (c) analyzing the structure of the oligosaccharides linked to the polypeptides to determine the glycoform pattern of the preparation.

The methods may further comprise altering the culture conditions of step (a) to achieve a second set of predetermined culture conditions; and repeating the steps until a desired glycoform pattern is achieved. Alternatively, the methods may further comprise treating the preparation chemically or enzymatically to alter the oligosaccharide structure; and repeating the steps until a desired glycoform pattern is achieved. Furthermore, the methods may comprise the additional steps of subjecting preparations having predetermined glycoform patterns to at least one test of bioactivity or other functionality (such as, e.g., pharmacokinetic profile or stability), and correlating particular glycoform patterns with particular bioactivity or functionality profiles.

In another aspect, the invention provides methods for producing a preparation comprising Factor VII polypeptides or Factor VII-related polypeptides having a predetermined pattern of N-linked glycosylation. In some embodiments, the methods are carried out by culturing a cell expressing the polypeptides under conditions in which at least about 94% of the

asparagine-linked oligosaccharides linked to the Factor VII polypeptides or Factor VII-related polypeptides comprise at least one sialic acid residue, e.g., one, two, three, or four sialic acid residues. In some embodiments, the methods are carried out by culturing a cell expressing the polypeptides under conditions in which at least about 5% of the oligosaccharide chains 5 contain at least one fucose linked α 1->3 to an antennary N-acetylglucosamine residue. In some embodiments, Factor VII polypeptides or Factor VII-related polypeptides, irrespective of their source, are subjected to enzymatic treatments to achieve the desired glycoform patterns.

In another aspect, the invention provides pharmaceutical formulations comprising 10 the preparations of the invention and methods of preventing and/or treating syndromes that are responsive to Factor VII polypeptides or Factor VII-related polypeptides. The methods comprise administering the pharmaceutical formulations to a patient in need of treatment, under conditions that result in either an enhancement or inhibition in blood clotting. In one series of embodiments, Factor VII preparations are administered when it is desired to enhance blood clotting, such as, e.g., in haemophilia A, haemophilia B, Factor XI deficiency, 15 Factor VII deficiency, thrombocytopenia, or von Willebrand's disease; in syndromes accompanied by the presence of a clotting factor inhibitor; before, during, or after surgery or anticoagulant therapy; or after trauma. In another series of embodiments, preparations of Factor VII-related polypeptides (i.e., preparations having reduced or modified bioactivity relative to 20 wild-type Factor VII) are administered to reduce blood clotting, such as, e.g., in patients undergoing angioplasty or those suffering from deep vein thrombosis, pulmonary embolism, stroke, disseminated intravascular coagulation (DIC), fibrin deposition in lungs and kidneys associated with gram-negative endotoxemia, or myocardial infarction. According to the invention, preparations of Factor VII-related polypeptides may also be administered when it is 25 desired to modify, such as, e.g., reduce, intracellular signalling via a tissue factor (TF)-mediated pathway, to treat conditions such as, e.g., Acute Respiratory Distress Syndrome (ARDS), Systemic Inflammatory Response Syndrome (SIRS), Hemolytic Uremic Syndrome (HUS), Multiple Organ Failure (MOF), and thrombocytopenia purpura (TTP).

30 **Detailed Description of the Invention**

The present inventors have discovered that preparations of coagulation proteins having predetermined glycoform patterns exhibit improved functional properties. Accordingly, the present invention relates to methods and compositions that provide these protein preparations. In particular, the invention relates to preparations comprising Factor VII polypeptides and Factor VII-related polypeptides having specific predetermined patterns of as- 35

paragine-linked (N-linked) oligosaccharides. The preparations of the invention exhibit altered properties, including, without limitation, improved pharmacokinetic properties and improved clinical efficacy. The invention also encompasses pharmaceutical formulations that comprise these preparations, as well as therapeutic methods that utilize the formulations.

5

Factor VII Polypeptides and Factor VII-Related Polypeptides

The present invention encompasses human Factor VII polypeptides, such as, e.g., those having the amino acid sequence disclosed in U.S. Patent No. 4,784,950 (wild-type Factor VII). As used herein, "Factor VII" or "Factor VII polypeptide" encompasses wild-type Factor VII, as well as variants of Factor VII exhibiting substantially the same or improved biological activity relative to wild-type Factor VII. The term "Factor VII" is intended to encompass Factor VII polypeptides in their uncleaved (zymogen) form, as well as those that have been proteolytically processed to yield their respective bioactive forms, which may be designated Factor VIIa. Typically, Factor VII is cleaved between residues 152 and 153 to yield Factor VIIa.

As used herein, "Factor VII-related polypeptides" encompasses polypeptides, including variants, in which the Factor VIIa biological activity has been substantially modified or reduced relative to the activity of wild-type Factor VIIa. These polypeptides include, without limitation, Factor VII or Factor VIIa that has been chemically modified and Factor VII variants into which specific amino acid sequence alterations have been introduced that modify or disrupt the bioactivity of the polypeptide.

The biological activity of Factor VIIa in blood clotting derives from its ability to (i) bind to tissue factor (TF) and (ii) catalyze the proteolytic cleavage of Factor IX or Factor X to produce activated Factor IX or X (Factor IXa or Xa, respectively). For purposes of the invention, Factor VIIa biological activity may be quantified by measuring the ability of a preparation to promote blood clotting using Factor VII-deficient plasma and thromboplastin, as described, e.g., in U.S. Patent No. 5,997,864. In this assay, biological activity is expressed as the reduction in clotting time relative to a control sample and is converted to "Factor VII units" by comparison with a pooled human serum standard containing 1 unit/ml Factor VII activity. Alternatively, Factor VIIa biological activity may be quantified by (i) measuring the ability of Factor VIIa to produce of Factor Xa in a system comprising TF embedded in a lipid membrane and Factor X. (Persson et al., *J. Biol. Chem.* 272:19919-19924, 1997); (ii) measuring Factor X hydrolysis in an aqueous system (see, Example 5 below); (iii) measuring its physical binding to TF using an instrument based on surface plasmon resonance (Persson, *FEBS Letts.* 413:359-363, 1997) (iv)

measuring hydrolysis of a synthetic substrate (see, Example 4 below); and (v) measuring generation of thrombin in a TF-independent *in vitro* system.

Factor VII variants having substantially the same or improved biological activity relative to wild-type Factor VIIa encompass those that exhibit at least about 25%, preferably at least about 50%, more preferably at least about 75% and most preferably at least about 90% of the specific activity of wild-type Factor VIIa that has been produced in the same cell type, when tested in one or more of a clotting assay, proteolysis assay, or TF binding assay as described above. Factor VII variants having substantially reduced biological activity relative to wild-type Factor VIIa are those that exhibit less than about 25%, preferably less than about 10%, more preferably less than about 5% and most preferably less than about 1% of the specific activity of wild-type Factor VIIa that has been produced in the same cell type when tested in one or more of a clotting assay, proteolysis assay, or TF binding assay as described above. Factor VII variants having a substantially modified biological activity relative to wild-type Factor VII include, without limitation, Factor VII variants that exhibit TF-independent Factor X proteolytic activity and those that bind TF but do not cleave Factor X.

Variants of Factor VII, whether exhibiting substantially the same or better bioactivity than wild-type Factor VII, or, alternatively, exhibiting substantially modified or reduced bioactivity relative to wild-type Factor VII, include, without limitation, polypeptides having an amino acid sequence that differs from the sequence of wild-type Factor VII by insertion, deletion, or substitution of one or more amino acids. Non-limiting examples of Factor VII variants having substantially the same biological activity as wild-type Factor VII include S52A-FVIIa, S60A-FVIIa (Iino et al., *Arch. Biochem. Biophys.* 352: 182-192, 1998); FVIIa variants exhibiting increased proteolytic stability as disclosed in U.S. Patent No. 5,580,560; Factor VIIa that has been proteolytically cleaved between residues 290 and 291 or between residues 315 and 316 (Mollerup et al., *Biotechnol. Bioeng.* 48:501-505, 1995); and oxidized forms of Factor VIIa (Kornfelt et al., *Arch. Biochem. Biophys.* 363:43-54, 1999). Non-limiting examples of Factor VII variants having substantially reduced or modified biological activity relative to wild-type Factor VII include R152E-FVIIa (Wildgoose et al., *Biochem.* 29:3413-3420, 1990), S344A-FVIIa (Kazama et al., *J. Biol. Chem.* 270:66-72, 1995), FFR-FVIIa (Holst et al., *Eur. J. Vasc. Endovasc. Surg.* 15:515-520, 1998), and Factor VIIa lacking the Gla domain, (Nicolaisen et al., *FEBS Letts.* 317:245-249, 1993). Non-limiting examples of chemically modified Factor VII polypeptides and sequence variants are described, e.g., in U.S. Patent No. 5,997,864.

Asparagine-Linked Glycosylation

The present invention provides preparations of Factor VII polypeptides or Factor VII-related polypeptides that comprise a particular spectrum of Factor VII glycoforms, i.e., Factor VII polypeptides or Factor VII-related polypeptides having predetermined patterns of asparagine-linked (N-linked) oligosaccharide chains.

As used herein, a "pattern" of N-linked glycosylation or a glycoform "pattern", "distribution", or "spectrum" refers to the representation of particular oligosaccharide structures within a given population of Factor VII polypeptides or Factor VII-related polypeptides. Non-limiting examples of such patterns include the relative proportion of oligosaccharide chains that (i) have at least one sialic acid residue; (ii) lack any sialic acid residues (i.e., are neutral in charge); (iii) have at least one terminal galactose residue; (iv) have at least one terminal N-acetylgalactosamine residue; (v) have at least one "uncapped" antenna, i.e., have at least one terminal galactose or N-acetylgalactosamine residue; or (vi) have at least one fucose linked α 1->3 to an antennary N-acetylglucosamine residue.

As used herein, an oligosaccharide chain refers to the entire oligosaccharide structure that is covalently linked to a single asparagine residue. Factor VII is normally glycosylated at Asn 145 and Asn 322. An N-linked oligosaccharide chain present on Factor VII produced in a human *in situ* may be bi-, tri, or tetraantennary, with each antenna having the structure Neu5Ac(α 2->3 or α 2->6)Gal(β 1->4) GlcNAc linked (β 1->2,4, or 6) to a Man residue which is linked (α 1->3 or 6) to Man(β 1->4)GlcNAc(β 1->4)GlcNAc-Asn. (Neu5Ac signifies N-acetylneurameric acid (sialic acid), Gal signifies galactose, GlcNAc signifies N-acetylglucosamine, and Man signifies mannose). The oligosaccharide chains may also comprise fucose residues, which may be linked α 1->6 to GlcNAc. When Factor VII is produced in a human *in situ*, some of the oligosaccharide chains lack core fucose residues; all of the chains lack antennary fucose residues; and all of the chains are almost completely sialylated, i.e., the terminal sugar of each antenna is N-acetylneurameric acid linked to galactose via an α 2->3 or α 2->6 linkage.

When produced in other circumstances, however, Factor VII may contain oligosaccharide chains having different terminal structures on one or more of their antennae, such as, e.g., lacking sialic acid residues; containing N-glycolylneurameric acid (Neu5Gc) residues; containing a terminal N-acetylgalactosamine (GalNAc) residue in place of galactose; and the like. When produced in, e.g., BHK cells cultured in the presence of calf serum, Factor VII preparations exhibit the following oligosaccharide patterns:

- 87-93% of the oligosaccharide chains contain at least a single sialic acid residue;
- 35 --7-13% are neutral (lack any sialic acid);

--9-16% contain at least one terminal galactose residue;
--19-29% contain at least one terminal N-acetylgalactosamine residue; and
--30-39% contain at least one uncapped antenna, i.e., contain at least one terminal galactose or N-acetylgalactosamine residue.

5 The present inventors have produced Factor VII preparations containing specific predetermined oligosaccharide patterns that differ from those previously described. The present invention encompasses preparations comprising Factor VII polypeptides or Factor VII-related polypeptides exhibiting one or more of the following glycoform patterns:

10 (i) Between about 94-100% of the oligosaccharide chains contain at least one sialic acid residue, such as, e.g., between about 94-99%, between about 95-98%, or between about 96-97%. In different embodiments, at least about 94%, 95%, 96%, or 97% of the oligosaccharide chains contain at least one sialic acid residue.

15 (ii) 6% or less of the oligosaccharide chains are neutral, such as, e.g., between about 1.5-6% or between about 2-4%.

(iii) Less than about 16%, preferably, less than about 10% of the oligosaccharide chains contain at least one terminal galactose, such as, e.g., between about 6-10% or between about 8-9%;

20 (iv) Less than about 25%, preferably, less than about 10% of the oligosaccharide chains contain at least one terminal GalNAc residue, such as, e.g., between about 6-9% or between about 7-8%;

(v) Less than about 30, preferably, less than about 25% of the oligosaccharide chains contain at least one uncapped antenna, such as, e.g., between about 11-23% or between about 12-18%; and

25 (vi) At least about 2%, preferably, at least about 5%, more preferably, at least about 10% or 20%; and most preferably, at least about 40%, of the oligosaccharide chains contain at least one fucose linked α 1->3 to an antennary N-acetylglucosamine residue (i.e., an N-acetylglucosamine residue that is linked β 1->2,4, or 6 to a Man residue).

It will be understood that each of (i)-(vi) may represent a distinct glycoform pattern that is encompassed by the present invention, i.e., a preparation according to the invention may be described by only one of (i)-(vi). Alternatively, depending on the particular glycoform pattern, a preparation encompassed by the invention may be described by more than one of (i)-(vi).

Furthermore, a preparation encompassed by the invention may be described by one or more of (i)-(vi) in combination with one or more other structural features. For example, the

invention encompasses preparations comprising Factor VII polypeptides or Factor VII-related polypeptides in which the sialic acid residues (Neu5Ac or Neu5Gc) are linked to galactose exclusively in an α 2->3 configuration. The invention also encompasses preparations comprising Factor VII polypeptides or Factor VII-related polypeptides that contain fucose linked α

5 1->6 to a core N-acetylglucosamine and/or fucose linked α 1->3 to an antennary N-acetylglucosamine. In one series of embodiments, the preparations of the invention encompass Factor VII or Factor VII-related polypeptides in which more than 99% of the oligosaccharide chains contain at least one sialic acid residue and (a) the sialic acid residues are linked exclusively in an α 2->3 configuration and/or (b) there are fucose residues linked to

10 core N-acetylglucosamines and/or (c) a detectable number of antenna terminate in N-acetylgalactosamine. In one embodiment, the invention encompasses preparations comprising wild-type Factor VIIa in which more than 99% of the oligosaccharide chains contain at least one sialic acid residue and the sialic acid residues are linked to galactose exclusively in an α 2->3 configuration. In another embodiment, the invention encompasses preparations

15 comprising wild-type Factor VIIa in which more than 99% of the oligosaccharide chains contain at least one sialic acid residue and at least some of the oligosaccharide chains comprise N-acetylgalactosamine. The present invention does not encompass wild-type Factor VII or wild-type Factor VIIa that is isolated from human plasma and is not modified *ex vivo* by treatment with glycosidases.

20 In one embodiment, the Factor VIIa preparation comprises oligosaccharide chains having a single fucose linked α 1->3 to one antennary N-acetylglucosamine. In another embodiment, the Factor VIIa preparation comprises oligosaccharide chains having fucose residues linked α 1->3 to each antennary N-acetylglucosamine of a biantennary oligosaccharide (Sialyl Lewis X structure). In another embodiment, the Factor VIIa preparation comprises

25 oligosaccharide chains having (i) a fucose linked to a core N-acetylglucosamine and (ii) a single fucose linked α 1->3 to one antennary N-acetylglucosamine. In another embodiment, the Factor VIIa preparation comprises oligosaccharide chains having (i) a fucose linked to a core N-acetylglucosamine and (ii) fucose residues linked α 1->3 to each antennary N-acetylglucosamine of a biantennary oligosaccharide.

30 In practicing the present invention, the pattern of N-linked oligosaccharides may be determined using any method known in the art, including, without limitation: high-performance liquid chromatography (HPLC); capillary electrophoresis (CE); nuclear magnetic resonance (NMR); mass spectrometry (MS) using ionization techniques such as fast-atom bombardment, electrospray, or matrix-assisted laser desorption (MALDI); gas chromatogra-

phy (GC); and treatment with exoglycosidases in conjunction with anion-exchange (AIE)-HPLC, size-exclusion chromatography (SEC), or MS. See, e.g., Weber et al., *Anal. Biochem.* 225:135 (1995); Klausen et al., *J. Chromatog.* 718:195 (1995); Morris et al., in *Mass Spectrometry of Biological Materials*, McEwen et al., eds., Marcel Dekker, (1990), pp 137-167; Conboy et al., *Biol. Mass Spectrom.* 21:397, 1992; Hellerqvist, *Meth. Enzymol.* 193:554 (1990); Sutton et al., *Anal. Biochem.* 318:34 (1994); Harvey et al., *Organic Mass Spectrometry* 29:752 (1994).

Following resolution of Factor VII-derived oligosaccharide chains using any of the above methods (or any other method that resolves oligosaccharide chains having 10 different structures), the resolved species are assigned, e.g., to one of groups (i)-(v). The relative content of each of (i)-(v) is calculated as the sum of the oligosaccharides assigned to that group relative to the total content of oligosaccharide chains in the sample.

For example, using AIE-HPLC, 13 or more N-linked oligosaccharide peaks can be 15 resolved from a recombinant Factor VII preparation produced in BHK cells. See, e.g., Klausen et al., *Mol. Biotechnol.* 9:195, 1998. Five of the peaks (designated 1-5 in Klausen et al.) do not contain sialic acid, while eight of the peaks (designated 6, 7, and 10-15) do contain sialic acid.

It will be understood that, in a given analysis, the number and distribution of sialic 20 acid-containing and sialic acid-lacking chains may depend upon (a) the polypeptide being expressed; (b) the cell type and culture conditions; and (c) the method of analysis that is employed, and that the resulting patterns may vary accordingly.

In any case, once the sialic acid-containing oligosaccharides have been resolved 25 from the non-sialic acid-containing oligosaccharides, conventional data analysis programs are used to calculate the area under each peak; the total peak area; and the percentage of the total peak area represented by a particular peak. In this manner, for a given preparation, the sum of the areas of sialic acid-containing peaks/total peak area X 100 yields the % sialylation value for the preparation according to the present invention (i.e., the proportion of oligosaccharide chains having at least one sialic acid residue). 30 In a similar manner, the % of chains having no sialic acid or at least one galactose or N-acetylglucosamine can be calculated.

Methods for Producing Factor VII Preparations Having a Predetermined Pattern of N-linked Oligosaccharides

Preparations of Factor VII, Factor VII variants, or Factor VII-related polypeptides, each having a predetermined pattern of N-linked oligosaccharides, may be produced using any appropriate host cell that expresses Factor VII or Factor VII-related polypeptides.

Host cells: In some embodiments, the host cells are human cells expressing an endogenous Factor VII gene. In these cells, the endogenous gene may be intact or 10 may have been modified *in situ*, or a sequence outside the Factor VII gene may have been modified *in situ* to alter the expression of the endogenous Factor VII gene. Any human cell capable of expressing an endogenous Factor VII gene may be used.

In other embodiments, heterologous host cells are programmed to express human Factor VII from a recombinant gene. The host cells may be vertebrate, insect, or fungal 15 cells. Preferably, the cells are mammalian cells capable of the entire spectrum of mammalian N-linked glycosylation; O-linked glycosylation; and γ -carboxylation. See, e.g., U.S. Patent Nos. 4,784,950. Preferred mammalian cell lines include the CHO (ATCC CCL 61), COS-1 (ATCC CRL 1650), baby hamster kidney (BHK) and HEK293 (ATCC CRL 1573; Graham et al., *J. Gen. Virol.* 36:59-72, 1977) cell lines. A preferred BHK cell line is the tk⁻ ts13 BHK cell 20 line (Waechter and Baserga, *Proc.Natl.Acad.Sci.USA* 79:1106-1110, 1982), hereinafter referred to as BHK 570 cells. The BHK 570 cell line is available from the American Type Culture Collection, 12301 Parklawn Dr., Rockville, MD 20852, under ATCC accession number CRL 10314. A tk⁻ ts13 BHK cell line is also available from the ATCC under accession number CRL 1632. In addition, a number of other cell lines may be used, including Rat Hep I 25 (Rat hepatoma; ATCC CRL 1600), Rat Hep II (Rat hepatoma; ATCC CRL 1548), TCMK (ATCC CCL 139), Human lung (ATCC HB 8065), NCTC 1469 (ATCC CCL 9.1) and DUKX cells (CHO cell line) (Urlaub and Chasin, *Proc. Natl. Acad. Sci. USA* 77:4216-4220, 1980). (DUKX cells also referred to as CXB11 cells), and DG44 (CHO cell line) (*Cell*, 33:405, 1983, and *Somatic Cell and Molecular Genetics* 12:555, 1986). Also useful are 3T3 cells, 30 Namalwa cells, myelomas and fusions of myelomas with other cells. In a particularly preferred embodiment, the host cells are BHK 21 cells that have been adapted to grow in the absence of serum and have been programmed to express Factor VII. In some embodiments, the cells may be mutant or recombinant cells that express a qualitatively or quantitatively different spectrum of glycosylation enzymes (such as, e.g., glycosyl transferases and/or glycosidases) 35 than the cell type from which they were derived. The cells may also be programmed to express other heterologous peptides or proteins, including, e.g., truncated forms of Factor VII.

In one embodiment, the host cells are CHO cells that have been programmed to co-express both the Factor VII polypeptide of interest (i.e., Factor VII or a Factor-VII-related polypeptide) and another heterologous peptide or polypeptide such as, e.g., a modifying enzyme or a Factor VII fragment.

5 **Methods:** The present invention encompasses methods for producing a preparation comprising any of the glycoform patterns described above as (i)-(vi) and, in further embodiments, methods for optimizing the glycoform distribution of Factor VII and Factor VII-related polypeptides. These methods are carried out by the steps of:

(a) culturing a cell expressing Factor VII or Factor VII-related polypeptides under a
10 first set of predetermined culture conditions;

(b) recovering Factor VII or Factor VII-related polypeptides from the culture to obtain a preparation comprising the polypeptides; and

(c) analyzing the structure of the oligosaccharides linked to the polypeptides to determine a glycoform pattern.

15 The methods may further comprise:

(d1) altering the culture conditions of step (a) to achieve a second set of predetermined culture conditions;

(e1) repeating steps (b)-(d1) until a desired glycoform pattern is achieved.

Alternatively, the methods may further comprise

20 (d2) treating the preparation chemically and/or enzymatically to alter the oligosaccharide structure; and

(e2) repeating steps (b)-(d2) until a desired glycoform pattern is achieved.

These methods may further comprise the step of subjecting preparations having predetermined glycoform patterns to at least one test of bioactivity (including, e.g., clotting, 25 Factor X proteolysis, or TF binding) or other functionality (such as, e.g., pharmacokinetic profile or stability), and correlating particular glycoform patterns with particular bioactivity or functionality profiles in order to identify a desired glycoform pattern.

The variables in the culture conditions that may be altered in step (d1) include, without limitation: the cell of origin, such as, e.g., a cell derived from a different species than originally used; or a mutant or recombinant cell having alterations in one or more glycosyl-transferases or glycosidases or other components of the glycosylation apparatus (see, Grabenhorst et al., *Glycoconjugate J.* 16:81, 1999; Bragonzi et al., *Biochem. Biophys. Acta* 1474:273, 2000; Weikert, *Nature Biotechnol.* 17:1116, 1999); the level of expression of the polypeptide; the metabolic conditions such as, e.g., glucose or glutamine concentration; the absence or presence of serum; the concentration of vitamin K; protein hydrolysates, hor-

mones, trace metals, salts as well as process parameters like temperature, dissolved oxygen level and pH.

- The enzymatic treatments that may be used in step (d2) to modify the oligosaccharide pattern of a preparation include, without limitation, treatment with one or more of sialidase (neuraminidase), galactosidase, fucosidase; galactosyl transferase, fucosyl transferase, and/or sialyltransferase, in a sequence and under conditions that achieve a desired modification in the distribution of oligosaccharide chains having particular terminal structures. Glycosyl transferases are commercially available from Calbiochem (La Jolla, CA) and glycosidases are commercially available from Glyko, Inc., (Novato, CA).
- In one series of embodiments, host cells expressing Factor VII or a related polypeptide are subjected to specific culture conditions in which they secrete glycosylated Factor VII polypeptides having the desired pattern of oligosaccharide structures described above as any of (i)-(vi). Such culture conditions include, without limitation, a reduction in, or complete absence of, serum. Preferably, the host cells are adapted to grow in the absence of serum and are cultured in the absence of serum both in the growth phase and in the production phase. Such adaptation procedures are described, e.g., in Scharfenberg, et al., *Animal Cell Technology Developments towards the 21st Century*, E. C. Beuvery et al. (Eds.), Kluwer Academic Publishers, pp. 619-623, 1995 (BHK and CHO cells); Cruz, *Biotechnol. Tech.* 11:117-120, 1997 (insect cells); Keen, *Cytotechnol.* 17:203-211, 1995 (myeloma cells); Berg et al., *Biotechniques* 14:972-978, 1993 (human kidney 293 cells). In a preferred embodiment, the growth medium that is added to the cells contains no protein or other component that was isolated from an animal tissue or an animal cell culture. See, e.g., Example 1 below. Typically, in addition to conventional components, a medium suitable for producing Factor VII contains Vitamin K at a concentration between 0.1-50 mg/liter, which is required for γ -carboxylation of glutamine residues in Factor VII.

In another series of embodiments, the glycoforms of the invention are produced by subjecting a preparation of Factor VII or Factor VII-related polypeptides to enzymatic and/or chemical modification of the N-linked oligosaccharides contained therein.

30

Factor VII Preparations

As used herein, a "Factor VII preparation" refers to a plurality of Factor VII polypeptides, Factor VIIa polypeptides, or Factor VII-related polypeptides, including variants and chemically modified forms, that have been separated from the cell in which they were synthesized.

Separation of polypeptides from their cell of origin may be achieved by any method known in the art, including, without limitation, removal of cell culture medium containing the desired product from an adherent cell culture; centrifugation or filtration to remove non-adherent cells; and the like.

5 Optionally, Factor VII polypeptides may be further purified. Purification may be achieved using any method known in the art, including, without limitation, affinity chromatography, such as, e.g., on an anti-Factor VII antibody column (see, e.g., Wakabayashi et al., *J. Biol. Chem.* 261:11097, 1986; and Thim et al., *Biochem.* 27:7785, 1988); hydrophobic interaction chromatography; ion-exchange chromatography; size exclusion chromatography; 10 electrophoretic procedures (e.g., preparative isoelectric focusing (IEF), differential solubility (e.g., ammonium sulfate precipitation), or extraction and the like. See, generally, Scopes, *Protein Purification*, Springer-Verlag, New York, 1982; and *Protein Purification*, J.-C. Janson and Lars Ryden, editors, VCH Publishers, New York, 1989. Following purification, the preparation preferably contains less than about 10% by weight, more preferably less than about 15 5% and most preferably less than about 1%, of non-Factor VII proteins derived from the host cell.

Factor VII and Factor VII-related polypeptides may be activated by proteolytic cleavage, using Factor XIIa or other proteases having trypsin-like specificity, such as, e.g., Factor IXa, kallikrein, Factor Xa, and thrombin. See, e.g., Osterud et al., *Biochem.* 11:2853 (1972); 20 Thomas, U.S. Patent No. 4,456,591; and Hedner et al., *J. Clin. Invest.* 71:1836 (1983). Alternatively, Factor VII may be activated by passing it through an ion-exchange chromatography column, such as Mono Q® (Pharmacia) or the like. The resulting activated Factor VII may then be formulated and administered as described below.

25 ***Functional Properties of Factor VII Preparations***

The preparations of Factor VII polypeptides and Factor VII-related polypeptides having predetermined oligosaccharide patterns according to the invention exhibit improved functional properties relative to reference preparations. The improved functional properties may include, without limitation, a) physical properties such as, e.g., storage 30 stability; b) pharmacokinetic properties such as, e.g., bioavailability and half-life; and c) immunogenicity in humans.

A reference preparation refers to a preparation comprising a polypeptide that is identical to that contained in the preparation of the invention to which it is being compared (such as, e.g., wild-type Factor VII or a particular variant or chemically modified 35 form) except for exhibiting a different pattern of asparagine-linked glycosylation. For

example, reference preparations typically comprise one or more of the following glycoform patterns: (i) less than about 93% (such as, e.g. less than about 92% or less than about 90%) of the oligosaccharide chains contain at least one sialic acid residue; (ii) at least about 6% (such as, e.g., at least about 7.5% or at least about 10%) of the oligosaccharide chains lack any sialic acid (i.e., are neutral); (iii) at least about 10% (such as, e.g., at least about 12.5% or at least about 15%) of the oligosaccharide chains contain at least one terminal galactose residue; (iv) at least about 15% (such as, e.g., at least about 20% or at least about 25%) of the oligosaccharide chains contain at least one terminal N-acetylgalactosamine residue; (v) at least about 25% (such as, e.g., at least about 30% or at least about 35%) of the oligosaccharide chains contain at least one uncapped antenna (i.e., contain at least one terminal galactose or N-acetylgalactosamine residue); or (vi) essentially undetectable levels (such as, e.g., less than about 0.2%) of antennary fucose residues.

Storage stability of a Factor VII preparation may be assessed by measuring (a) the time required for 20% of the bioactivity of a preparation to decay when stored as a dry powder at 25°C and/or (b) the time required for a doubling in the proportion of Factor VIIa aggregates in the preparation.

In some embodiments, the preparations of the invention exhibit an increase of at least about 30%, preferably at least about 60% and more preferably at least about 100%, in the time required for 20% of the bioactivity to decay relative to the time required for the same phenomenon in a reference preparation, when both preparations are stored as dry powders at 25°C. Bioactivity measurements may be performed using any of a clotting assay, proteolysis assay, TF-binding assay, or TF-independent thrombin generation assay.

In some embodiments, the preparations of the invention exhibit an increase of at least about 30%, preferably at least about 60%, and more preferably at least about 100%, in the time required for doubling of aggregates relative to a reference preparation, when both preparations are stored as dry powders at 25°C. The content of aggregates is determined by gel permeation HPLC on a Protein Pak 300 SW column (7.5 x 300 mm) (Waters, 80013) as follows. The column is equilibrated with Eluent A (0.2 M ammonium sulfate, 5 % isopropanol, pH adjusted to 2.5 with phosphoric acid, and thereafter pH is adjusted to 7.0 with triethylamine), after which 25 µg of sample is applied to the column. Elution is with Eluent A at a flow rate of 0.5 ml/min for 30 min, and detection is achieved by measuring absorbance at 215 nm. The content of aggregates is calculated as the peak area of the Factor VII aggregates/total area of Factor VII peaks (monomer and aggregates).

"Bioavailability" refers to the proportion of an administered dose of a Factor VII or Factor VII-related preparation that can be detected in plasma at predetermined times after administration. Typically, bioavailability is measured in test animals by administering a dose of between about 25-250 µg/kg of the preparation; obtaining plasma samples at predetermined times after administration; and determining the content of Factor VII or Factor VII-related polypeptides in the samples using one or more of a clotting assay (or any bioassay), an immunoassay, or an equivalent. The data are typically displayed graphically as [Factor VII] v. time and the bioavailability is expressed as the area under the curve (AUC). Relative bioavailability of a test preparation refers to the ratio between the AUC of the test preparation and that of the reference preparation.

In some embodiments, the preparations of the present invention exhibit a relative bioavailability of at least about 110%, preferably at least about 120%, more preferably at least about 130% and most preferably at least about 140% of the bioavailability of a reference preparation. The bioavailability may be measured in any mammalian species, preferably dogs, and the predetermined times used for calculating AUC may encompass different increments from 10 min- 8 h.

"Half-life" refers to the time required for the plasma concentration of Factor VII polypeptides of Factor VII-related polypeptides to decrease from a particular value to half of that value. Half-life may be determined using the same procedure as for bioavailability. In some embodiments, the preparations of the present invention exhibit an increase in half-life of at least about 0.25 h, preferably at least about 0.5 h, more preferably at least about 1 h, and most preferably at least about 2 h, relative to the half-life of a reference preparation.

"Immunogenicity" of a preparation refers to the ability of the preparation, when administered to a human, to elicit a deleterious immune response, whether humoral, cellular, or both. Factor VIIa polypeptides and Factor VIIa-related polypeptides are not known to elicit detectable immune responses in humans. Nonetheless, in any human sub-population, there may exist individuals who exhibit sensitivity to particular administered proteins. Immunogenicity may be measured by quantifying the presence of anti-Factor VII antibodies and/or Factor VII-responsive T-cells in a sensitive individual, using conventional methods known in the art. In some embodiments, the preparations of the present invention exhibit a decrease in immunogenicity in a sensitive individual of at least about 10%, preferably at least about 25%, more preferably at least about 40% and most preferably at least about 50%, relative to the immunogenicity for that individual of a reference preparation.

Pharmaceutical Compositions and Methods of Use

The preparations of the present invention may be used to treat any Factor VII-responsive syndrome, such as, e.g., bleeding disorders, including, without limitation, those caused by clotting factor deficiencies (e.g., haemophilia A and B or deficiency of coagulation factors XI or VII); by thrombocytopenia or von Willebrand's disease, or by clotting factor inhibitors, or excessive bleeding from any cause. The preparations may also be administered to patients in association with surgery or other trauma or to patients receiving anticoagulant therapy.

Preparations comprising Factor VII-related polypeptides according to the invention, which have substantially reduced bioactivity relative to wild-type Factor VII, may be used as anticoagulants, such as, e.g., in patients undergoing angioplasty or other surgical procedures that may increase the risk of thrombosis or occlusion of blood vessels as occurs, e.g., in restenosis. Other medical indications for which anticoagulants are prescribed include, without limitation, deep vein thrombosis, pulmonary embolism, stroke, disseminated intravascular coagulation (DIC), fibrin deposition in lungs and kidneys associated with gram-negative endotoxemia, myocardial infarction; Acute Respiratory Distress Syndrome (ARDS), Systemic Inflammatory Response Syndrome (SIRS), Hemolytic Uremic Syndrome (HUS), MOF, and TTP.

Pharmaceutical compositions comprising the Factor VII and Factor VII-related preparations according to the present are primarily intended for parenteral administration for prophylactic and/or therapeutic treatment. Preferably, the pharmaceutical compositions are administered parenterally, i.e., intravenously, subcutaneously, or intramuscularly. They may be administered by continuous or pulsatile infusion.

Pharmaceutical compositions or formulations comprise a preparation according to the invention in combination with, preferably dissolved in, a pharmaceutically acceptable carrier, preferably an aqueous carrier or diluent. A variety of aqueous carriers may be used, such as water, buffered water, 0.4% saline, 0.3% glycine and the like. The preparations of the invention can also be formulated into liposome preparations for delivery or targeting to the sites of injury. Liposome preparations are generally described in, e.g., U.S. Patents Nos. 4,837,028, 4,501,728, and 4,975,282. The compositions may be sterilised by conventional, well-known sterilisation techniques. The resulting aqueous solutions may be packaged for use or filtered under aseptic conditions and lyophilised, the lyophilised preparation being combined with a sterile aqueous solution prior to administration.

The compositions may contain pharmaceutically acceptable auxiliary substances or adjuvants, including, without limitation, pH adjusting and buffering agents and/or tonicity

adjusting agents, such as, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, etc.

The concentration of Factor VII or Factor VII-related polypeptides in these formulations can vary widely, i.e., from less than about 0.5% by weight, usually at or at least 5 about 1% by weight to as much as 15 or 20% by weight and will be selected primarily by fluid volumes, viscosities, etc., in accordance with the particular mode of administration selected.

Thus, a typical pharmaceutical composition for intravenous infusion could be made up to contain 250 ml of sterile Ringer's solution and .10 mg of the preparation. Actual methods for preparing parenterally administrable compositions will be known or apparent to 10 those skilled in the art and are described in more detail in, for example, *Remington's Pharmaceutical Sciences*, 18th ed., Mack Publishing Company, Easton, PA (1990).

The compositions containing the preparations of the present invention can be administered for prophylactic and/or therapeutic treatments. In therapeutic applications, compositions are administered to a subject already suffering from a disease, as described 15 above, in an amount sufficient to cure, alleviate or partially arrest the disease and its complications. An amount adequate to accomplish this is defined as "therapeutically effective amount". Effective amounts for each purpose will depend on the severity of the disease or injury as well as the weight and general state of the subject. In general, however, the effective amount will range from about 0.05 mg up to about 500 mg of the preparation per 20 day for a 70 kg subject, with dosages of from about 1.0 mg to about 200 mg of the preparation per day being more commonly used. It will be understood that determining an appropriate dosage may be achieved using routine experimentation, by constructing a matrix of values and testing different points in the matrix.

Local delivery of the preparations of the present invention, such as, for 25 example, topical application, may be carried out, e.g., by means of a spray, perfusion, double balloon catheters, stent, incorporated into vascular grafts or stents, hydrogels used to coat balloon catheters, or other well established methods. In any event, the pharmaceutical compositions should provide a quantity of the preparation sufficient to effectively treat the subject.

30 The pharmaceutical compositions of the invention may further comprise other bioactive agents, such as, e.g., non-Factor VII-related coagulants or anticoagulants.

The following examples are intended as non-limiting illustrations of the present invention.

Example 1: Production and Analysis of a Factor VII preparation exhibiting an altered glycoform pattern

The following experiment was performed to produce a Factor VII preparation having an altered glycoform pattern.

5 I. *Production:* A BHK cell line transformed with a Factor VII-encoding plasmid was adapted to growth in suspension culture in the absence of serum. The cells were propagated sequentially in spinner cultures and as the cell number increased, the volume was gradually increased by addition of new medium.

10 Finally, 6 l of seed culture were inoculated into a 100-liter production bioreactor containing macroporous Cytopore 1 carriers (Pharmacia), after which the suspension cells became immobilized in the carriers. The culture was maintained at 36°C at a pH of 6.7–6.9 and a DO of 50%. The volume in the production bioreactor was gradually increased by addition of new medium as the cell number increased. When the cell density reached approximately 2×10^6 cells/ml, the production phase was initiated and a medium change was performed
15 every 24 hours: Agitation was stopped to allow for sedimentation of the cell-containing carriers, and 80% of the culture supernatant was then harvested and replaced with new medium. The harvested culture supernatant was filtered to remove non-trapped cells and cell debris and was then transferred for further processing.

During the production phase the cells reached $3\text{--}6 \times 10^6$ cells/ml and a titer of 2–7 mg
20 Factor VII/liter.

II. *Analysis of the glycoform pattern of recombinant Factor VII*

The oligosaccharide patterns of the following preparations were compared: (a) recombinant Factor VII preparations produced as described in part I ($n=7$); and two reference preparations: (b) recombinant Factor VII preparations produced in BHK cells in the presence of calf serum ($n=10$); and (c) a Factor VII preparation purified from human plasma.

30 The N-linked oligosaccharides were released from the polypeptides by chemical cleavage (hydrazinolysis, on a GlycoPrep1000 unit, Oxford GlycoSciences) or by enzymatic cleavage (N-glycosidase F from, eg., Boehringer Mannheim). The released oligosaccharides were labeled with 2-aminobenzamide (using a signal labelling kit, K-404, Oxford GlycoSciences or Glyko). The labeled oligosaccharides were analysed using anion-exchange HPLC on a CarboPac PA100 column (4x250 mm, Dionex, P/N 43055) with a Guard column (4x50 mm, Dionex, P/N 43054). The column was equilibrated with 150 mM sodium hydrox-

ide and eluted with a gradient of 0-150 mM sodium acetate, 150 mM sodium hydroxide. Oligosaccharides were detected using fluorescence, with excitation at 330 nm and emission at 420 nm.

The relative contents of the various Factor VII oligosaccharide structures (Klausen et al., 1998) were calculated as the relative peak areas for the carbohydrate peaks in the anion-exchange HPLC analysis. Based on the structural elements of each oligosaccharide, it was assigned to one of the following: (i) chains containing at least one sialic acid; (ii) chains lacking any sialic acid (i.e., neutral); (iii) chains containing at least one terminal galactose residue; (iv) chains containing at least one terminal N-acetylgalactosamine residue; and (v) chains containing at least one uncapped antenna (i.e., at least one terminal galactose or N-acetylgalactosamine residue). Finally, the sum of the relative contents of the oligosaccharide chains assigned to each group was calculated as a percentage of the total oligosaccharide chains. The standard deviation of this determination was calculated to be 0.08% (intraday variation); 0.7% (day-to-day variation); and 0.5% (1-100 µg interval).

The resulting glycoform patterns are illustrated in the following table:

	(i)	(ii)	(iii)	(iv)	(v)
a	93.1-98.7	1.3-6.9	5.9-16.4	5.9-8.7	11.7-23.9
b	88.3-92.5	7.5-12.9	9.4-16.8	19.0-28.6	30.1-39.0
c	99.5%	<0.5%	2-3%	0%	2-3%

The recombinant Factor VII preparations produced according to this Example (i.e., in the absence of serum) exhibit a glycoform pattern that differs from both the glycoform pattern of recombinant Factor VII produced in the presence of serum and native Factor VII isolated from human plasma. The oligosaccharides of recombinant Factor VII produced in the absence of serum are sialylated to a higher extent than those produced in the presence of serum and contain less neutral chains and less chains that terminate in either galactose or N-acetylgalactosamine.

III. Bioavailability:

The following experiment was performed to compare the bioavailability of two Factor VII preparations produced as above (I and II) with that of two reference Factor VII preparations (i.e., produced in the presence of serum) (A and B).

Groups of 8 rats were administered either a test preparation or a reference preparation at a dose of 25 µg/kg (~ 100 µg/rat) in a glycylglycine buffer (pH 7.4) containing sodium chloride (7.87 mg/ml), calcium chloride dihydrate (1.48 mg/ml), mannitol (2.5 mg/ml) and polysorbate 80. Blood samples were withdrawn at 10 min and 30 min following the initial administration. Plasma was obtained from the samples and Factor

VII was quantified by ELISA. Bioavailability of each sample is expressed as the dose-adjusted area under the plasma concentration curve for Factor VII based on the 10 and 30-min samples ($AUC_{10-30}/dose$). The relative bioavailability is expressed as the ratio between the mean $AUC_{10-30}/dose$ of the test and reference samples X 100. The 90% confidence limits for the relative bioavailability were calculated from the 90% confidence limits for differences between preparations.

- 5 The results are summarized in the Table below. (The % sialylation of each preparation, which was measured as described above, is indicated in parentheses).

test	reference	relative bioavailability	90% conf. lower	90% conf. upper
I (97.5%)	A (93%)	128.6	116.1	141.1
I (97.5%)	B (86%)	154.9	141.2	168.5
II (96.7%)	A 93%	117.3	104.8	129.8
II (96.7%)	B (86%)	141.2	127.5	154.8

10

15

The results indicate that even relatively small differences in the proportion of oligosaccharide chains having at least one sialic acid residue, such as, e.g., between 93% and 96 or 97%, can have a marked impact on bioavailability (increase of 20-30%).

20 A 10% increase in the % sialylation, moreover, causes a 40-50% increase in bioavailability.

Example 2: Analysis of Factor VII preparations exhibiting an altered glycoform pattern

Factor VII was produced as described in Example 1 above, with the exception that the Factor VII was harvested from 500-l cultures. Glycoform analysis was performed as described in Example 1. Three independent preparations (A, B, and C) were analyzed and compared with a reference preparation (D).

5 Bioavailability was measured in a dog model as follows: The experiment was performed as a four leg cross-over study in 12 Beagle dogs divided in four groups. All animals received each of the three test preparations A, B, and C and the reference preparation D at a dose of ≈90 µg/kg in a glycylglycine buffer (pH 5.5) containing sodium chloride (2.92 mg/ml), calcium chloride dihydrate (1.47 mg/ml), mannitol (30 mg/ml) and polysorbate 80. Blood
10 samples were withdrawn at 10, 30, and 60 minutes and 2, 3, 4, 6 and 8 hours following the initial administration. Plasma was obtained from the samples and Factor VII was quantified by ELISA.

15 Bioavailability of each sample is expressed as the dose-adjusted area under the plasma concentration curve for Factor VII (AUC/dose). The relative bioavailability is expressed as the ratio between the mean AUC/dose of the test and reference preparation X 100 and 90% confidence limits for the relative bioavailability were calculated.

The results are summarized in the Table below. The % sialylation of each preparation, which was measured as described in Example 1 above, is indicated in parentheses.

20

Test	Reference	Relative bioavailability	90% conf.limit lower	90% conf.limit upper
A (98.7%)	D (88.2%)	144	135	153
B (95.9%)	D (88.2%)	127	119	136
C (93.1%)	D (88.2%)	112	105	120

25 The results indicate that small differences in the proportion of oligosaccharide chains having at least one sialic acid residue have a marked impact on bioavailability of Factor VII. A 10% increase in the % sialylation causes a 30-50% increase in bioavailability with a close to linear relationship for the three test preparations and the reference preparation

Example 3: Factor VII preparations exhibiting an altered glycoform pattern

The following experiment was performed to produce a Factor VII preparation having an altered glycoform pattern.

1. Construction of cell line and Factor VII production:

A plasmid vector pLN174 for expression of human FVII has been described (Persson and Nielsen. 1996. *FEBS Lett.* 385: 241-243). Briefly, it carries the cDNA nucleotide sequence encoding human FVII including the propeptide under the control of a mouse metallothionein promoter for transcription of the inserted cDNA, and mouse dihydrofolate reductase cDNA under the control of an SV40 early promoter for use as a selectable marker.

For construction of a plasmid vector encoding a gamma-carboxylation recognition sequence, a cloning vector (pBluescript II KS+, Stratagene) containing cDNA encoding FVII including its propeptide was used (pLN171). (Persson et al. 1997. *J. Biol. Chem.* 272: 19919-19924). A nucleotide sequence encoding a stop codon was inserted into the cDNA encoding FVII after the propeptide of FVII by inverse PCR-mediated mutagenesis using this cloning vector. The template plasmid was denatured by treatment with NaOH followed by PCR with Pwo (Boehringer-Mannheim) and Taq (Perkin-Elmer) polymerases with the following primers:

15

- a) 5'-AGC GTT TTA GCG CCG GCG CCG GTG CAG GAC-3'
- b) 5'-CGC CGG CGC TAA AAC GCT TTC CTG GAG GAG CTG CGG CC-3'

The resulting mix was digested with DpnI to digest residual template DNA and *Escherichia coli* were transformed with the PCR product. Clones were screened for the presence of the mutation by sequencing. The cDNA from a correct clone was transferred as a BamHI-EcoRI fragment to the expression plasmid pcDNA3 (Invitrogen). The resulting plasmid was termed pLN329. CHO K1 cells (ATCC CCl61) were transfected with equal amounts of pLN174 and pLN329 with the Fugene6 method (Boehringer-Mannheim). Transfectants were selected by the addition of methotrexate to 1 μ M and G-418 to 0.45 mg/ml. The pool of transfectants were cloned by limiting dilution and FVII expression from the clones was measured.

A high producing clone was further subcloned and a clone E11 with a specific FVII expression of 2.4 pg/cell/day in Dulbecco-modified Eagle's medium with 10 % fetal calf serum was selected. The clone was adapted to serum free suspension culture in a commercially available CHO medium (JRH Bioscience) free of animal derived components.

The adapted cells were propagated sequentially in spinner cultures and as the cell number increased, the volume was gradually increased by addition of new medium. After 25 days, 6 l of spinner culture were inoculated into a 50-liter bioreactor. The cells

were propagated in the bioreactor and as the cell number increased, the volume was gradually increased by addition of new medium.

Finally, 50 l of seed culture were inoculated into a 500-liter production bioreactor containing macroporous Cytopore 1 carriers (Pharmacia), after which the suspension cells became immobilized in the carriers. The culture was maintained at 36°C at a pH of 7.0-7.1 and a Dissolved Oxygen Tension (DOT) of 50% of saturation. The volume in the bioreactor was gradually increased by addition of new medium as the cell number increased. When the cell density reached approximately $10\text{-}12 \times 10^5$ cells/ml, the production phase was initiated and a medium change was performed every 24 hours: agitation was stopped to allow for sedimentation of the cell-containing carriers, and 80% of the culture supernatant was then harvested and replaced with new medium. The harvested culture supernatant was filtered to remove non-trapped cells (i.e. cells that were not immobilized in carriers) and cell debris and was then transferred for further processing.

During the production phase the cells reached $2\text{-}3 \times 10^7$ cells/ml and a titer of 8 mg Factor VII/liter.

II. Glycoform Analysis:

A. The oligosaccharide pattern of a Factor VII preparation produced as described above (a) was compared with those of (b) recombinant Factor VII preparations produced in BHK cells in the presence of calf serum and (c) a Factor VII preparation purified from human plasma. The methods used were essentially as described in Example 1.

The results are shown in the Table below. The oligosaccharide assignments are as follows: (i) chains containing at least one sialic acid; (ii) chains lacking any sialic acid (i.e., neutral); (iii) chains containing at least one terminal galactose residue; (iv) chains containing at least one terminal N-acetylgalactosamine residue; and (v) chains containing at least one uncapped antenna (i.e., at least one terminal galactose or N-acetylgalactosamine residue).

30

	(I)	(ii)	(iii)	(iv)	(v)
a	95.2	4.8	22.9	0.1	23.0
b	88.3-92.5	7.5-12.9	9.4-16.8	19.0-28.6	30.1-39.0
c	99.5%	<0.5%	2-3%	0%	2-3%

B. The oligosaccharide patterns of five independent Factor VII preparations produced as described in this Example (a) were compared with those of (b) recombinant Factor VII preparations produced in BHK cells in the presence of calf serum and (c) a Factor VII preparation purified from human plasma, using the analytical methods 5 described in Example 1.

Based on the structural elements of each oligosaccharide, it was assigned to one of the following: (i) chains containing at least one sialic acid; (ii) chains lacking any sialic acid (i.e., neutral); (iii) chains containing at least one fucose linked to the antenna. Finally, the sum of the relative contents of the oligosaccharide chains assigned to each group was calculated as a percentage of the total oligosaccharide chains. The standard deviation of this determination was calculated to be 0.08% (intraday variation); 0.7% (day-to-day variation); and 10 0.5% (1-100 µg interval).

The resulting glycoform patterns are illustrated in the following Table:

	(i)	(ii)	(iii)
a	89.0-97.9%	2.1-11.0%	6.3-21.3%
b	88.3-92.5%	7.5-12.9%	0%
c	99.5%	<0.5%	0%

15

The recombinant Factor VII preparations produced according to Example 1 (i.e., produced in the absence of serum by the CHO cell line) exhibit a glycoform pattern that differs from both the glycoform pattern of recombinant Factor VII produced in the presence of serum and native Factor VII isolated from human plasma. The oligosac-20 charides of recombinant Factor VII produced in the absence of serum by the CHO 282.4 cell line include structures with fucose linked to the antenna, which are absent from both of the reference preparations. Two of the structures have been purified and characterized by matrix assisted laser desorption ionisation mass spectrometry, by treatment with linkage specific fucosidase enzymes and by anion-exchange HPLC as 25 described above. The two structures have been shown to contain the sialyl Lewis x structure, i.e., fucose linked α 1->3 to an antennary N-acetylglucosamine in a sialylated oligosaccharide.

III. Bioactivity:

30 Five Factor VII preparations produced as described in this Example were analyzed for (a) thrombin generation and (b) binding to tissue factor (TF) and compared

with recombinant Factor VII produced in BHK cells in the presence of serum (reference). The following Table correlates the glycoform patterns (% of oligosaccharide chains containing sialic acid and the % containing fucosylated antenna) and the two bioactivities.

5

Factor VII Preparation	Oligosaccharide Pattern		Thrombin generation (% of reference)	TF binding Kd (nM)
	% Sialyl	%Fucosyl		
1	98	6	125	2.8
2	94	13	123	2.0
3	93	14	126	1.8
4	88	16	145	3.3
5	86	21	158	2.8
reference	86-93	0	100	2.2-6.6

The results indicate that Factor VII preparations having fucosylated antennae exhibit higher TF-independent Factor VII activity (as exhibited, e.g. by thrombin generation) than Factor VII preparations lacking fucosylated antennae.

10

Example 4: In Vitro Hydrolysis Assay

The following method can be used to assay Factor VIIa bioactivity. The assay is carried out in a microtiter plate (MaxiSorp, Nunc, Denmark). The chromogenic substrate D-Ile-Pro-Arg-p-nitroanilide (S-2288, Chromogenix, Sweden), at a final concentration of 1 mM, is added to Factor VIIa (final concentration 100 nM) in 50 mM Hepes, pH 7.4, containing 0.1 M NaCl, 5 mM CaCl₂ and 1 mg/ml bovine serum albumin. The absorbance at 405 nm is measured continuously in a SpectraMax™ 340 plate reader (Molecular Devices, USA). The absorbance developed during a 20-minute incubation, after subtraction of the absorbance in a blank well containing no enzyme, is used to calculate the ratio between the activities of a test and a reference Factor VIIa.

Example 5: In Vitro Proteolysis Assay

The following method can be used to assay Factor VIIa bioactivity. The assay is carried out in a microtiter plate (MaxiSorp, Nunc, Denmark). Factor VIIa (10 nM) and Factor X (0.8 microM) in 100 µl 50 mM Hepes, pH 7.4, containing 0.1 M NaCl, 5 mM CaCl₂ and 1 mg/ml bovine serum albumin, are incubated for 15 min. Factor X cleavage is then stopped

by the addition of 50 μ l 50 mM H_epes, pH 7.4, containing 0.1 M NaCl, 20 mM EDTA and 1 mg/ml bovine serum albumin. The amount of Factor Xa generated is measured by addition of the chromogenic substrate Z-D-Arg-Gly-Arg-p-nitroanilide (S-2765, Chromogenix, Sweden), final concentration 0.5 mM. The absorbance at 405 nm is measured continuously in a 5 SpectraMax™ 340 plate reader (Molecular Devices, USA). The absorbance developed during 10 minutes, after subtraction of the absorbance in a blank well containing no FVIIa, is used to calculate the ratio between the proteolytic activities of a test and a reference Factor VIIa.

10

All patents, patent applications, and literature references referred to herein are hereby incorporated by reference in their entirety.

Many variations of the present invention will suggest themselves to those skilled in the art in light of the above detailed description. Such obvious variations are within the full 15 intended scope of the appended claims.

Claims:

1. A preparation comprising a plurality of Factor VII polypeptides or Factor VII-related polypeptides, wherein the polypeptides comprise asparagine-linked oligosaccharide chains and wherein between about 94-99% of the oligosaccharide chains comprise at least one sialic acid moiety.
5
2. A preparation comprising a plurality of Factor VII polypeptides or Factor VII-related polypeptides, wherein the polypeptides comprise asparagine-linked oligosaccharide chains and wherein between about 1-7% of the oligosaccharide chains have a neutral charge.
10
3. A preparation comprising a plurality of Factor VII polypeptides or Factor VII-related polypeptides, wherein the polypeptides comprise asparagine-linked oligosaccharide chains and wherein between about 6-16% of the oligosaccharide chains comprise at least one terminal galactose residue.
15
4. A preparation comprising a plurality of Factor VII polypeptides or Factor VII-related polypeptides, wherein the polypeptides comprise asparagine-linked oligosaccharide chains and wherein between about 6-9% of the oligosaccharide chains comprise at least one terminal N-acetylgalactosamine residue.
20
5. A preparation comprising a plurality of Factor VII polypeptides or Factor VII-related polypeptides, wherein the polypeptides comprise asparagine-linked oligosaccharide chains and wherein between about 11-23% of the oligosaccharide chains comprise at least one terminal galactose or N-acetylgalactosamine residue.
25
6. A preparation comprising a plurality of Factor VII polypeptides or Factor VII-related polypeptides, wherein the polypeptides comprise asparagine-linked oligosaccharide chains and wherein at least about 2% of the oligosaccharide chains comprise at least one fucose moiety linked α 1->3 to an antennary N-acetylglucosamine.
30
7. A preparation as defined in any of claims 1-6, wherein the sialic residues in the oligosaccharide chains are linked to galactose via an α 2->3 linkage.

8. A preparation as defined in any of claims 1-7, wherein the sialic acid residues comprise N-acetylneuraminic acid (Neu5Ac) and N-glycolylneuraminic acid (Neu5Gc).
9. A preparation as defined in any of claims 1-8, wherein the oligosaccharides comprise
5 fucose linked α 1->6 to a core N-acetylglucosamine.
10. A preparation as defined in any of claims 1-9, wherein between about 95-98% of the oli-
gosaccharide chains contain at least one sialic acid residue.
- 10 11. A preparation as defined in any of claims 1-10, wherein between about 96-97% of the
oligosaccharide chains contain at least one sialic acid residue.
12. A preparation as defined in any of claims 1-11, wherein between about 2-4% of the oli-
gosaccharide chains have a neutral charge.
- 15 13. A preparation as defined in any of claims 1-12, wherein between about 8-12% of the oli-
gosaccharide chains contain at least one terminal galactose residue.
14. A preparation as defined in any of claims 1-13, wherein between about 7-8% of the oli-
20 gosaccharide chains contain at least one terminal N-acetylgalactosamine residue.
15. A preparation as defined in any of claims 1-14, wherein between about 12-18% of the
oligosaccharide chains contain at least one terminal galactose or N-acetylgalactosamine
residue.
- 25 16. A preparation as defined in any of claims 1-15, wherein at least about 5% of the oli-
gosaccharide chains comprise at least one fucose moiety linked α 1->3 to an antennary
N-acetylglucosamine.
- 30 17. A preparation as defined in any of claims 1-16, wherein at least about 10% of the
oligosaccharide chains comprise at least one fucose moiety linked α 1->3 to an anten-
nary N-acetylglucosamine.

18. A preparation as defined in any of claims 1-17, wherein at least about 20% of the oligosaccharide chains comprise at least one fucose moiety linked α 1->3 to an antennary N-acetylglucosamine.
- 5 19. A preparation as defined in any of claims 1-18, wherein at least about 40% of the oligosaccharide chains comprise at least one fucose moiety linked α 1->3 to an antennary N-acetylglucosamine
- 10 20. A preparation as defined in any of claims 1-19, wherein the polypeptides have the amino acid sequence of wild-type Factor VII.
21. A preparation as defined in any of claims 1-20, wherein the polypeptides are wild-type Factor VIIa.
- 15 22. A preparation as defined in any of claims 1-19, wherein the Factor VII polypeptides are selected from the group consisting of: S52A-Factor VII, S60A-Factor VII, Factor VII that has been proteolytically cleaved between residues 290 and 291; Factor VII that has been proteolytically cleaved between residues 315 and 316; and Factor VII that has been oxidized.
- 20 23. A preparation as defined in any of claims 1-19, wherein the Factor VII-related polypeptides are selected from the group consisting of: R152E-Factor VII, S344A-Factor VII, FFR-Factor VII, and Factor VIIa lacking the Gla domain.
- 25 24. A preparation comprising a plurality of Factor VII polypeptides or Factor VII-related polypeptides, wherein the polypeptides comprise asparagine-linked oligosaccharide chains and wherein (i) between about 94-100% of the oligosaccharide chains comprise at least one sialic acid moiety and (ii) between about 6-9% of the oligosaccharide chains comprise at least one terminal N-acetylgalactosamine residue.
- 30 25. A preparation as defined in claim 24, wherein the Factor VII polypeptides have the sequence of wild-type Factor VII.
- 35 26. A preparation comprising a plurality of Factor VIIa polypeptides having the sequence of wild-type Factor VII, wherein the polypeptides comprise asparagine-linked oligosaccharide

chains and wherein between about 94-99% of the oligosaccharide chains comprise at least one sialic acid residue.

27. A preparation comprising a plurality of Factor VIIa polypeptides having the sequence of
5 wild-type Factor VII, wherein the polypeptides comprise asparagine-linked oligosaccharide chains and wherein at least about 2% of the oligosaccharide chains comprise at least one fucose moiety linked α 1->3 to an antennary N-acetylglucosamine.
28. A preparation as defined in any of claims 1-27, wherein the polypeptides are produced in
10 a host cell selected from the group consisting of fungal, insect, and vertebrate cells.
29. A preparation as defined in claim 28, wherein the host cell is a mammalian cell.
30. A preparation as defined in claim 29, wherein the mammalian cell is derived from a ham-
15 ster.
31. A preparation as defined in claim 30, wherein the hamster cell is selected from the group consisting of CHO cells and BHK cells.
- 20 32. A preparation as defined in claim 29, wherein the mammalian cell is derived from a hu-
man.
33. A preparation as defined in claim 32, wherein the human cell is an HEK cell.
- 25 34. A preparation as defined in any of claims 1-33, wherein the preparation exhibits a bioavailability that is at least about 110% of the bioavailability of a reference preparation, wherein about 93% or less of the oligosaccharide chains in the reference preparation comprise at least one sialic acid moiety.
- 30 35. A preparation as defined in claim 34, wherein the preparation exhibits a bioavailability that is at least about 120% of the bioavailability of the reference preparation.
36. A preparation as defined in claim 35, wherein the preparation exhibits a bioavailability that is at least about 130% of the bioavailability of the reference preparation.

37. A preparation as defined in claim 36, wherein the preparation exhibits a bioavailability that is at least about 140% of the bioavailability of the reference preparation.

38. A method for determining the glycoform pattern of Factor VII and Factor VII-related poly-peptides, the method comprising:

(a) culturing a cell expressing Factor VII or Factor VII-related polypeptides under a first set of predetermined culture conditions;

(b) recovering Factor VII or Factor VII-related polypeptides from the culture to obtain a preparation comprising the polypeptides; and

(c) analyzing the structure of the oligosaccharides linked to the polypeptides to determine the glycoform pattern of the preparation.

39. A method as defined in claim 38, further comprising

(d1) altering the culture conditions of step (a) to achieve a second set of predetermined culture conditions;

(e1) repeating steps (b)-(d1) until a desired glycoform pattern is achieved.

40. A method as defined in claim 38, further comprising:

(d2) treating the preparation chemically or enzymatically to alter the oligosaccharide structure; and

(e2) repeating steps (b)-(d2) until a desired glycoform pattern is achieved.

41. A method for producing a preparation comprising Factor VII polypeptides or Factor VII-related polypeptides having a predetermined pattern of N-linked glycosylation, said method comprising culturing a cell expressing the polypeptides under conditions in which at least about 94% of the asparagine-linked oligosaccharides present on the polypeptides comprise at least one sialic acid residue.

42. A pharmaceutical formulation comprising a preparation as defined in any of claims 1-37 and a pharmaceutically acceptable carrier or adjuvant.

43. A method for treating a Factor VII-responsive syndrome, the method comprising administering a pharmaceutical formulation as defined in claim 42 to a patient in need of such treatment, under conditions that result in a decrease in bleeding and/or an increase in blood clotting, wherein the formulation comprises Factor VII polypeptides.

44. A method as defined in claim 43, wherein the syndrome is selected from the group consisting of haemophilia A, haemophilia B, Factor XI deficiency, Factor VII deficiency, thrombocytopenia, von Willebrand's disease, presence of a clotting factor inhibitor, surgery, trauma,
5 and anticoagulant therapy.
45. A method for preventing unwanted bleeding, the method comprising administering a pharmaceutical formulation as defined in claim 42 to a patient in need of such treatment, under conditions that result in a decrease in bleeding and/or an increase in blood clotting,
10 wherein the formulation comprises Factor VII polypeptides.
46. A method for preventing unwanted blood clotting, the method comprising administering a pharmaceutical formulation as defined in claim 42 to a patient in need of such treatment, under conditions effective for inhibiting coagulation, wherein the formulation comprises Factor
15 VII-related polypeptides.
47. A method for preventing tissue factor mediated reactions, the method comprising administering a pharmaceutical formulation as defined in claim 42 to a patient in need of such treatment, under conditions effective for inhibiting coagulation, wherein the formulation comprises Factor VII-related polypeptides.
20
48. A method as defined in claim 46, wherein the unwanted blood clotting is associated with a condition selected from the group consisting of: angioplasty, deep vein thrombosis,
25 pulmonary embolism, stroke, disseminated intravascular coagulation (DIC), fibrin deposition in lungs and kidneys associated with gram-negative endotoxemia, and myocardial infarction.
49. A method as defined in claim 47, wherein the tissue factor mediated reactions are asosicated with a condition selected from the group consisting of SIRS, ARDS, MOF,HUS,
30 and TTP.
50. Use of a preparation comprising Factor VII polypeptides or Factor VII-related polypeptides as defined in any of claims 1-37 for the preparation of a medicament for treating a Factor VII-responsive syndrome.

51. Use as defined in claim 50, wherein the syndrome is selected from the group consisting of haemophilia A, haemophilia B, Factor XI deficiency, Factor VII deficiency, thrombocytopenia, von Willebrand's disease, presence of a clotting factor inhibitor, surgery, trauma, and anticoagulant therapy.

5

52. Use of a preparation comprising Factor VII polypeptides or Factor VII-related polypeptides as defined in any of claims 1-37 for the preparation of a medicament for prevention of unwanted bleeding.

10 53. Use of a preparation comprising Factor VII polypeptides or Factor VII-related polypeptides as defined in any of claims 1-37 for the preparation of a medicament for prevention of unwanted blood clotting.

15 54. Use as defined in claim 53, wherein the unwanted blood clotting is associated with a condition selected from the group consisting of: angioplasty, deep vein thrombosis, pulmonary embolism, stroke, disseminated intravascular coagulation (DIC), fibrin deposition in lungs and kidneys associated with gram-negative endotoxemia, and myocardial infarction.

20 55. Use of a preparation comprising Factor VII polypeptides or Factor VII-related polypeptides as defined in any of claims 1-37 for the preparation of a medicament for preventing tissue factor-mediated reactions.

25 56. Use as defined in claim 55, wherein the tissue factor mediated reactions are associated with a condition selected from the group consisting of SIRS, ARDS, MOF, HUS, and TTP.

INTERNATIONAL SEARCH REPORT

Int.	lational Application No
PCT/DK 01/00633	

A. CLASSIFICATION OF SUBJECT MATTER				
IPC 7	C12N9/64	A61K38/36	C12P21/02	G01N33/86

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C12P C07K A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
--

WPI Data, EPO-Internal, PAJ, BIOSIS, MEDLINE
--

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>KEMBALL-COOK G ET AL.: "High-level production of human blood coagulation factors VII and XI using a new mammalian expression vector." GENE (AMSTERDAM), vol. 139, no. 2, 1994, pages 275-279, XP002203071 ISSN: 0378-1119 abstract page 277, left-hand column, line 3 -page 278, right-hand column, line 9 table 1 figure 2</p> <p>----</p> <p>-/-</p>	1-56

<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.
--

<input checked="" type="checkbox"/> Patent family members are listed in annex.
--

* Special categories of cited documents:
--

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the International search report
--

11 July 2002

29/07/2002

Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel: (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016
--

Authorized officer

van de Kamp, M

INTERNATIONAL SEARCH REPORT

Int

Serial Application No

PCT/DK 01/00633

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	KLAUSEN N K ET AL.: "Analysis of the site-specific asparagine-linked glycosylation of recombinant human coagulation factor VIIa by glycosidase digestions, liquid chromatography, and mass spectroscopy." MOLECULAR BIOTECHNOLOGY, vol. 9, no. 3, June 1998 (1998-06), pages 195-204, XP008005265 ISSN: 1073-6085 cited in the application abstract ---	1-56
Y	KLAUSEN N K ET AL.: "Analysis of the glycoforms of human recombinant factor VIIa by capillary electrophoresis and high-performance liquid chromatography" JOURNAL OF CHROMATOGRAPHY A,, vol. 718, no. 1, 1 December 1995 (1995-12-01), pages 195-202, XP004038516 ISSN: 0021-9673 cited in the application abstract ---	1-56
Y	WEBER P L ET AL.: "Characterization of glycopeptides from recombinant coagulation factor VIIa by high-performance liquid chromatography and capillary zone electrophoresis using ultraviolet and pulsed electrochemical detection." ANALYTICAL BIOCHEMISTRY, vol. 225, no. 1, 1995, pages 135-142, XP002203677 ISSN: 0003-2697 cited in the application abstract ---	1-56
Y	THIM L ET AL.: "Amino acid sequence and posttranslational modifications of human factor VII-a from plasma and transfected baby hamster kidney cells" BIOCHEMISTRY, vol. 27, no. 20, 1988, pages 7785-7793, XP002203678 ISSN: 0006-2960 abstract page 7791, right-hand column, line 3 -page 7792, right-hand column, line 16 --- -/-	1-56

INTERNATIONAL SEARCH REPORT

Int'l	Applicant Application No
PCT/DK 01/00633	

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	BJOERN S ET AL.: "Human plasma and recombinant factor VII. Characterization of O-glycosylations at serine residues 52 and 60 and effects of site-directed mutagenesis of serine 52 to alanine" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 266, no. 17, 1991, pages 11051-11057, XP002203679 ISSN: 0021-9258 abstract ---	1-56
Y	US 6 100 061 A (MUNDT WOLFGANG ET AL) 8 August 2000 (2000-08-08) the whole document column 4, line 32-47 ---	1-56
Y	WO 00 28065 A (WIBERG FINN C ;NOVONORDISK AS (DK); WOELDIKE HELLE (DK); NIELSEN L) 18 May 2000 (2000-05-18) page 4, line 1-16 ---	1-56
Y	US 4 784 950 A (HAGEN FREDERICK S ET AL) 15 November 1988 (1988-11-15) cited in the application column 2, line 59 -column 5, line 2 example 6 ---	1-56
Y	US 5 580 560 A (NICOLAISEN ELSE M ET AL) 3 December 1996 (1996-12-03) cited in the application column 3, line 45 -column 6, line 24 ---	1-56
Y	GOUDEMAND J: "Le facteur VII activé recombinant: un nouveau traitement de l'hémophilie" TRANSFUSION CLINIQUE ET BIOLOGIQUE, vol. 5, no. 4, August 1998 (1998-08), pages 260-265, XP001041135 ISSN: 1246-7820 abstract ---	1-56
Y	RODDIE P H ET AL.: "Recombinant coagulation factors" BLOOD REVIEWS, vol. 11, no. 4, December 1997 (1997-12), pages 169-177, XP001041136 abstract page 176, line 8 -page 177, line 13 ---	1-56
	-/-	

INTERNATIONAL SEARCH REPORT

In	onal Application No
PCT/DK 01/00633	

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>GAWLITZEK M ET AL.: "Characterization of changes in the glycosylation pattern of recombinant proteins from BHK-21 cells due to different culture conditions" JOURNAL OF BIOTECHNOLOGY, vol. 42, no. 2, 29 September 1995 (1995-09-29), pages 117-131, XP004036908 ISSN: 0168-1656 abstract page 118, left-hand column, line 1 -page 119, left-hand column, line 17 page 129, left-hand column, line 13 -right-hand column, line 12 ---</p>	1-56
Y	<p>BROAD D ET AL.: "Production of recombinant proteins in serum-free media" CYTOTECHNOLOGY, vol. 5, no. 1, 1991, pages 47-55, XP001073869 the whole document ---</p>	1-56
Y	<p>GRABENHORST E ET AL.: "Genetic engineering of recombinant glycoproteins and the glycosylation pathway in mammalian host cells." GLYCOCOCONJUGATE JOURNAL., vol. 16, no. 2, February 1999 (1999-02), pages 81-97, XP008005300 ISSN: 0282-0080 cited in the application abstract ---</p>	1-56
Y	<p>WEIKERT S ET AL.: "Engineering Chinese hamster ovary cells to maximize sialic acid content of recombinant glycoproteins." NATURE BIOTECHNOLOGY, vol. 17, no. 11, November 1999 (1999-11), pages 1116-1121, XP002203703 ISSN: 1087-0156 cited in the application abstract page 1116, left-hand column, line 1 -right-hand column, line 24 page 1119, right-hand column, line 27 -page 1120, left-hand column, line 65 ---</p>	1-56
	-/-	

INTERNATIONAL SEARCH REPORT

In	onal Application No
PCT/DK 01/00633	

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>BRAGONZI A ET AL.: "A new Chinese hamster ovary cell line expressing alpha2,6-sialyltransferase used as universal host for the production of human-like sialylated recombinant glycoproteins."</p> <p>BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1474, no. 3, 1 May 2000 (2000-05-01), pages 273-282, XP002203704 ISSN: 0006-3002 cited in the application abstract</p> <p>---</p>	1-56
T	<p>JURLANDER B ET AL.: "Recombinant activated factor VII (rFVIIa): Characterization, manufacturing, and clinical development."</p> <p>SEMINARS IN THROMBOSIS AND HEMOSTASIS, vol. 27, no. 4, August 2001 (2001-08), pages 373-384, XP008005254 ISSN: 0094-6176 the whole document</p> <p>-----</p>	

INTERNATIONAL SEARCH REPORT

International application No.
PCT/DK 01/00633

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 43–49 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple Inventions in this International application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int'l	Int'l Application No
PCT/DK	01/00633

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
US 6100061	A 08-08-2000	AT	407255 B 107397 A	26-02-2001 15-06-2000
WO 0028065	A 18-05-2000	AU WO EP US	1262900 A 0028065 A1 1127154 A1 6329176 B1	29-05-2000 18-05-2000 29-08-2001 11-12-2001
US 4784950	A 15-11-1988	AT AU AU CN DE DE DK EP ES ES FI GR HU HU IE JP JP JP JP JP JP JP JP JP JP JP JP JP LU NO NZ PT RU ZA	92105 T 603983 B2 5617786 A 86102644 A ,B 3688760 D1 3688760 T2 177386 A 0200421 A2 554038 D0 8800343 A1 861598 A 860984 A1 43634 A2 204556 B 61982 B 2107600 C 8024587 B 62000283 A 2835038 B2 10117787 A 2726806 B2 7163374 A 2544090 B2 7163375 A 88806 A9 175066 B 215842 A 82408 A ,B 2122583 C1 8602768 A	15-08-1993 06-12-1990 06-11-1986 03-06-1987 02-09-1993 28-10-1993 18-10-1986 05-11-1986 01-11-1987 01-01-1988 18-10-1986 18-08-1986 30-11-1987 28-01-1992 14-12-1994 06-11-1996 13-03-1996 06-01-1987 14-12-1998 12-05-1998 11-03-1998 27-06-1995 16-10-1996 27-06-1995 03-01-1997 16-05-1994 29-04-1988 01-05-1986 27-11-1998 30-12-1986
US 5580560	A 03-12-1996		NONE	